elfazepam    B-Sedative104166553
(    O
INN    O
)    O

This    O
plant    O
has    O
medicinal    O
value    O
and    O
it    O
contains    O
a    O
compound    O
named    O
Barakol    B-Sedative104166553
.    O

Diproqualone    B-Sedative104166553

Diproqualone    B-Sedative104166553
is    O
a    O
quinazolinone    B-Sedative104166553
class    O
GABAergic    O
and    O
is    O
an    O
analogue    O
of    O
methaqualone    O
developed    O
in    O
the    O
late    O
1950s    O
by    O
a    O
team    O
at    O
Nogentaise    O
de    O
Produits    O
Chimique    O
.    O

She    O
rode    O
on    O
the    O
Ramblin'    B-Sedative104166553
Wreck    I-Sedative104166553
and    O
appears    O
in    O
the    O
1972    O
Georgia    O
Tech    O
"    O
Blueprint    O
"    O
yearbook    O
.    O

President    O
Emeritus    O
G.    O
Wayne    O
Clough    O
and    O
current    O
Georgia    O
Tech    O
president    O
G.    O
P.    O
"    O
Bud    O
"    O
Peterson    O
in    O
front    O
of    O
the    O
Ramblin'    B-Sedative104166553
Wreck    I-Sedative104166553
on    O
the    O
site    O
of    O
the    O
Clough    O
Undergraduate    O
Learning    O
Commons    O
at    O
its    O
groundbreaking    O
on    O
April    O
5    O
,    O
2010    O
.    O

The    B-Sedative104166553
Ramblin'    I-Sedative104166553
Wreck    I-Sedative104166553
from    I-Sedative104166553
Georgia    I-Sedative104166553
Tech    I-Sedative104166553
-    O
A    O
1930    O
Ford    O
Model    O
A    O
Sport    O
Coupe    O
which    O
serves    O
as    O
the    O
official    O
mascot    O
of    O
the    O
student    O
body    O
at    O
the    O
Georgia    O
Institute    O
of    O
Technology    O

She    O
rode    O
on    O
the    O
Ramblin'    B-Sedative104166553
Wreck    I-Sedative104166553
and    O
appears    O
in    O
the    O
1972    O
Georgia    O
Tech    O
Blueprint    O
yearbook    O
.    O

Triclofos    B-Sedative104166553
is    O
a    O
sedative    O
drug    O
used    O
rarely    O
for    O
treating    O
insomnia    O
,    O
usually    O
as    O
a    O
second    O
-    O
line    O
treatment    O
after    O
other    O
drugs    O
have    O
failed    O
.    O

Loreclezole    B-Sedative104166553

Cartazolate    O
(    O
SQ-65,396    O
)    O
is    O
a    O
drug    O
of    O
the    O
pyrazolopyridine    B-Sedative104166553
class    O
.    O

Lurasidone    O
is    O
chemically    O
similar    O
to    O
Perospirone    B-Sedative104166553
(    O
also    O
a    O
chemical    O
analogue    O
of    O
Zeldox    O
)    O
,    O
as    O
well    O
as    O
Risperidone    O
,    O
Paliperidone    O
and    O
Iloperidone    O
.    O

Alnespirone    O
,    O
binospirone    O
,    O
and    O
enilospirone    O
,    O
despite    O
being    O
azapirones    O
,    O
are    O
not    O
piperazines    O
and    O
therefore    O
do    O
not    O
metabolize    O
to    O
1-PP    O
,    O
and    O
while    O
perospirone    B-Sedative104166553
and    O
tiospirone    B-Sedative104166553
are    O
piperazines    O
,    O
they    O
are    O
instead    O
benzothiazole    O
-    O
substituted    O
piperazines    O
and    O
do    O
not    O
metabolize    O
to    O
1-PP    O
either    O
.    O

Alnespirone    O
,    O
binospirone    O
,    O
and    O
enilospirone    O
,    O
despite    O
being    O
azapirones    O
,    O
are    O
not    O
piperazines    O
and    O
therefore    O
do    O
not    O
metabolize    O
to    O
1-PP    O
,    O
and    O
while    O
perospirone    B-Sedative104166553
and    O
tiospirone    B-Sedative104166553
are    O
piperazines    O
,    O
they    O
are    O
instead    O
benzothiazole    O
-    O
substituted    O
piperazines    O
and    O
do    O
not    O
metabolize    O
to    O
1-PP    O
either    O
.    O

Compounds    O
which    O
increased    O
"    O
SMN2    O
"    O
activity    O
"    O
in    O
vitro    O
"    O
but    O
did    O
not    O
make    O
it    O
to    O
the    O
clinical    O
stage    O
include    O
growth    O
hormone    O
,    O
various    O
histone    O
deacetylase    O
inhibitors    O
,    O
benzamide    B-Sedative104166553
M344    O
,    O
hydroxamic    O
acids    O
(    O
CBHA    O
,    O
SBHA    O
,    O
entinostat    O
,    O
panobinostat    O
,    O
trichostatin    O
A    O
,    O
vorinostat    O
)    O
,    O
prolactin    O
as    O
well    O
as    O
natural    O
polyphenol    O
compounds    O
like    O
resveratrol    O
and    O
curcumin    O
.    O

Metoclopramide    O
is    O
a    O
substituted    O
benzamide    B-Sedative104166553
;    O
cisapride    O
and    O
mosapride    O
are    O
structurally    O
related    O
.    O

In    O
the    O
laboratory    O
it    O
can    O
be    O
prepared    O
by    O
the    O
dehydration    O
of    O
benzamide    B-Sedative104166553
or    O
by    O
the    O
Rosenmund    O
-    O
von    O
Braun    O
reaction    O
using    O
cuprous    O
cyanide    O
or    O
NaCN    O
/    O
DMSO    O
and    O
bromobenzene    O
.    O

In    O
the    O
presence    O
of    O
ethyl    O
dichlorophosphate    O
and    O
DBU    O
benzamide    B-Sedative104166553
converts    O
to    O
benzonitrile    O
:    O

Liebig    O
and    O
WÃ¶hler    O
observed    O
in    O
1832    O
in    O
an    O
investigation    O
of    O
benzoin    O
resin    O
(    O
benzoic    O
acid    O
)    O
that    O
the    O
compounds    O
almond    O
oil    O
(    O
benzaldehyde    O
)    O
,    O
"    O
"    O
Benzoestoff    O
"    O
"    O
(    O
benzyl    O
alcohol    O
)    O
,    O
benzoyl    O
chloride    O
and    O
benzamide    B-Sedative104166553
all    O
share    O
a    O
common    O
C7H5O    O
fragment    O
and    O
that    O
these    O
compounds    O
could    O
all    O
be    O
synthesized    O
from    O
almond    O
oil    O
by    O
simple    O
substitutions    O
.    O

AzM    O
is    O
very    O
stable    O
when    O
dissolved    O
in    O
acidic    O
,    O
neutral    O
or    O
slightly    O
alkaline    O
water    O
but    O
above    O
pH11    O
it    O
is    O
rapidly    O
hydrolyzed    O
to    O
anthranilic    O
acid    O
,    O
benzamide    B-Sedative104166553
,    O
and    O
other    O
chemicals    O
.    O

3-Aminobenzamide    O
is    O
a    O
benzamide    B-Sedative104166553
.    O

Alternatively    O
,    O
the    O
patient    O
may    O
be    O
switched    O
to    O
a    O
longer    O
-    O
acting    O
gabaergic    B-Sedative104166553
agent    O
such    O
as    O
diazepam    O
(    O
in    O
a    O
manner    O
similar    O
to    O
the    O
use    O
of    O
methadone    O
therapy    O
for    O
opiate    O
addiction    O
)    O
before    O
attempting    O
de    O
-    O
titration    O
.    O

Alfaxalone    O
works    O
as    O
a    O
positive    O
allosteric    O
modulator    O
on    O
GABAA    O
receptors    O
and    O
,    O
at    O
high    O
concentrations    O
,    O
as    O
a    O
direct    O
agonist    B-Sedative104166553
of    O
the    O
GABAA    O
receptor    O
.    O

GABAA    B-Sedative104166553
agonists    I-Sedative104166553
,    O
usually    O
diazepam    O
but    O
sometimes    O
other    O
benzodiazepines    O
,    O
are    O
the    O
primary    O
treatment    O
for    O
SPS    O
.    O

Older    O
drugs    O
such    O
as    O
paraldehyde    O
and    O
clomethiazole    B-Sedative104166553
were    O
formerly    O
the    O
traditional    O
treatment    O
but    O
have    O
now    O
largely    O
been    O
superseded    O
by    O
the    O
benzodiazepines    O
.    O

Chlormethiazole    B-Sedative104166553

Piperidione    B-Sedative104166553
(    O
trade    O
name    O
Sedulon    B-Sedative104166553
)    O
is    O
a    O
sedative    O
drug    O
,    O
structurally    O
related    O
to    O
methyprylon    B-Sedative104166553
and    O
pyrithyldione    B-Sedative104166553
.    O

Pyrithyldione    B-Sedative104166553

Cariprazine    B-Sedative104166553

Cariprazine    B-Sedative104166553
,    O
sold    O
under    O
the    O
brand    O
names    O
Vraylar    B-Sedative104166553
in    O
the    O
United    O
States    O
and    O
Reagila    B-Sedative104166553
in    O
Europe    O
,    O
is    O
an    O
atypical    B-Sedative104166553
antipsychotic    I-Sedative104166553
which    O
is    O
used    O
in    O
the    O
treatment    O
of    O
schizophrenia    O
and    O
bipolar    O
mania    O
.    O

Antipsychotics    O
(    O
neuroleptics    O
or    O
tranquilizers    O
)    O
were    O
investigated    O
by    O
the    O
anesthesiologists    O
De    O
Castro    O
and    O
Mundeleer    O
who    O
coined    O
the    O
term    O
neuroleptanalgesia    B-Sedative104166553
,    O
an    O
anesthetic    O
process    O
that    O
involves    O
combining    O
a    O
major    O
neuroleptic    O
tranquilizer    O
/    O
antipsychotic    O
with    O
a    O
potent    O
opioid    O
analgesic    O
to    O
produce    O
a    O
detached    O
,    O
pain    O
-    O
free    O
state    O
.    O

Porfimer    O
is    O
Haematoporphyrin    B-Sedative104166553
Derivative    O
(    O
HpD    O
)    O
(    O
See    O
PDT    O
)    O
.    O

As    O
of    O
2013    O
,    O
the    O
10    O
most    O
prescribed    O
psychiatric    O
drugs    O
by    O
number    O
of    O
prescriptions    O
were    O
alprazolam    O
,    O
sertraline    O
,    O
citalopram    B-Sedative104166553
,    O
fluoxetine    O
,    O
lorazepam    O
,    O
trazodone    O
,    O
escitalopram    B-Sedative104166553
,    O
duloxetine    O
,    O
bupropion    O
XL    O
,    O
and    O
venlafaxine    B-Sedative104166553
XR    I-Sedative104166553
.    O

Citalopram    B-Sedative104166553
(    O
Celexa    O
)    O
,    O
SSRI    O

Selective    O
serotonin    O
reuptake    O
inhibitors    O
(    O
SSRIs    O
)    O
,    O
such    O
as    O
sertraline    O
(    O
Zoloft    O
,    O
Lustral    O
)    O
,    O
escitalopram    B-Sedative104166553
(    O
Lexapro    O
,    O
Cipralex    O
)    O
,    O
fluoxetine    O
(    O
Prozac    O
)    O
,    O
paroxetine    O
(    O
Seroxat    O
)    O
,    O
and    O
citalopram    B-Sedative104166553
,    O
are    O
the    O
primary    O
medications    O
considered    O
,    O
due    O
to    O
their    O
relatively    O
mild    O
side    O
effects    O
and    O
broad    O
effect    O
on    O
the    O
symptoms    O
of    O
depression    O
and    O
anxiety    O
,    O
as    O
well    O
as    O
reduced    O
risk    O
in    O
overdose    O
,    O
compared    O
to    O
their    O
older    O
tricyclic    O
alternatives    O
.    O

Citalopram    B-Sedative104166553

Patients    O
taking    O
the    O
selective    O
serotonin    O
reuptake    O
inhibitors    O
(    O
SSRIs    O
)    O
Paxil    O
(    O
paroxetine    O
HCl    O
)    O
or    O
Celexa    O
(    O
citalopram    B-Sedative104166553
)    O
have    O
been    O
observed    O
yawning    O
more    O
often    O
.    O

Pharmacological    O
interventions    O
include    O
the    O
use    O
of    O
SSRIs    O
,    O
such    O
as    O
fluvoxamine    O
,    O
citalopram    B-Sedative104166553
,    O
escitalopram    B-Sedative104166553
,    O
and    O
naltrexone    O

Many    O
other    O
SSRI    O
antidepressants    O
are    O
fluorinated    O
organics    O
,    O
including    O
Celexa    B-Sedative104166553
,    O
Luvox    O
,    O
and    O
Lexapro    B-Sedative104166553
.    O

One    O
small    O
study    O
of    O
patients    O
with    O
excoriation    O
disorder    O
treated    O
with    O
citalopram    B-Sedative104166553
,    O
another    O
SSRI    O
,    O
showed    O
that    O
those    O
that    O
took    O
the    O
drug    O
significantly    O
reduced    O
their    O
scores    O
on    O
the    O
Yale    O
-    O
Brown    O
Obsessive    O
Compulsive    O
Scale    O
compared    O
to    O
placebo    O
,    O
but    O
that    O
there    O
was    O
no    O
significant    O
decrease    O
on    O
the    O
visual    O
-    O
analog    O
scale    O
of    O
picking    O
behavior    O
.    O

These    O
medicines    O
included    O
the    O
antidepressants    O
Citalopram    B-Sedative104166553
and    O
Duloxetine    O
,    O
as    O
well    O
as    O
the    O
antitussive    O
Dextromethorphan    O
and    O
the    O
antihistamines    O
Diphenhydramine    O
and    O
Chlorpheniramine    O
.    O

Mirtazapine    O
is    O
considered    O
to    O
be    O
relatively    O
safe    O
in    O
the    O
event    O
of    O
an    O
overdose    O
,    O
although    O
it    O
is    O
considered    O
slightly    O
more    O
toxic    O
in    O
overdose    O
than    O
most    O
of    O
the    O
SSRIs    O
(    O
except    O
citalopram    B-Sedative104166553
)    O
.    O

Citalopram    B-Sedative104166553

It    O
was    O
shown    O
to    O
completely    O
reverse    O
the    O
autoreceptor    O
-    O
mediated    O
inhibition    O
of    O
serotonin    O
release    O
induced    O
by    O
the    O
administration    O
of    O
selective    O
serotonin    O
reuptake    O
inhibitors    O
like    O
citalopram    B-Sedative104166553
in    O
rodent    O
studies    O
.    O

In    O
level    O
one    O
,    O
patients    O
received    O
the    O
selective    O
serotonin    O
reuptake    O
inhibitor    O
(    O
SSRI    O
)    O
citalopram    B-Sedative104166553
for    O
up    O
to    O
14    O
weeks    O
,    O
with    O
adjustment    O
of    O
the    O
dose    O
being    O
managed    O
by    O
their    O
own    O
physicians    O
.    O

Citalopram    B-Sedative104166553

Etazolate    B-Sedative104166553

Piperidione    B-Sedative104166553
(    O
trade    O
name    O
Sedulon    B-Sedative104166553
)    O
is    O
a    O
sedative    O
drug    O
,    O
structurally    O
related    O
to    O
methyprylon    B-Sedative104166553
and    O
pyrithyldione    B-Sedative104166553
.    O

Methyprylon    B-Sedative104166553

Fenobam    B-Sedative104166553

Fenobam    B-Sedative104166553

Phenylethylmalonamide    B-Sedative104166553
(    O
PEMA    O
)    O
is    O
an    O
active    O
metabolite    O
of    O
the    O
anticonvulsant    O
drug    O
primidone    O
,    O
although    O
it    O
is    O
produced    O
in    O
a    O
much    O
lower    O
concentration    O
than    O
phenobarbital    O
,    O
the    O
other    O
active    O
metabolite    O
.    O

Probarbital    B-Sedative104166553
(    O
trade    O
names    O
Ipral    B-Sedative104166553
,    O
Vasalgin    B-Sedative104166553
)    O
is    O
a    O
barbiturate    O
derivative    O
invented    O
in    O
the    O
1920s    O
.    O

Against    O
timiperone    B-Sedative104166553
,    O
clocapramine    O
showed    O
lower    O
efficacy    O
against    O
both    O
positive    O
and    O
negative    O
symptoms    O
and    O
produced    O
more    O
side    O
effects    O
such    O
as    O
dyskinesia    O
,    O
insomnia    O
,    O
constipation    O
,    O
and    O
nausea    O
.    O

Valofane    B-Sedative104166553
tautomerises    O
to    O
Proxibarbal    O
in    O
vivo    O
.    O

Ethyl    O
loflazepate    O
was    O
designed    O
to    O
be    O
a    O
prodrug    O
for    O
descarboxyloflazepate    B-Sedative104166553
,    O
its    O
active    O
metabolite    O
.    O

DHA-clozapine    B-Sedative104166553
(    O
tentative    O
trade    O
name    O
Clozaprexin    B-Sedative104166553
)    O
is    O
an    O
atypical    O
antipsychotic    O
drug    O
candidate    O
that    O
was    O
created    O
and    O
originally    O
tested    O
by    O
chemists    O
at    O
Protarga    O
,    O
a    O
small    O
pharmaceutical    O
in    O
Pennsylvania    O
,    O
and    O
scientists    O
at    O
Harvard    O
University    O
.    O

He    O
would    O
show    O
them    O
a    O
carrier    O
bag    O
full    O
of    O
money    O
to    O
back    O
up    O
his    O
story    O
,    O
ply    O
them    O
with    O
champagne    O
that    O
had    O
been    O
drugged    B-Sedative104166553
with    O
sedatives    O
and    O
then    O
sexually    O
assault    O
or    O
rape    O
them    O
.    O

Date    B-Sedative104166553
rape    I-Sedative104166553
drug    I-Sedative104166553

The    O
guilty    O
verdicts    O
were    O
for    O
seven    O
charges    O
of    O
rape    O
,    O
one    O
of    O
attempted    O
rape    O
,    O
six    O
of    O
indecent    O
assault    O
,    O
two    O
of    O
stupefying    B-Sedative104166553
,    O
one    O
of    O
attempted    O
stupefying    O
,    O
two    O
of    O
wilful    O
ill    O
-    O
treatment    O
of    O
a    O
child    O
,    O
three    O
of    O
assault    O
on    O
a    O
female    O
,    O
and    O
one    O
of    O
bestiality    O
.    O

A    O
fruit    O
-    O
flavoured    O
date    B-Sedative104166553
rape    I-Sedative104166553
drug    I-Sedative104166553
in    O
Hong    O
Kong    O

Progesterex    O
is    O
a    O
fictitious    O
date    B-Sedative104166553
rape    I-Sedative104166553
drug    I-Sedative104166553
that    O
would    O
purportedly    O
cause    O
sterilization    O
.    O

Ilan    O
Kutz    O
suggests    O
that    O
today    O
it    O
would    O
be    O
called    O
"    O
drug    B-Sedative104166553
rape    I-Sedative104166553
"    O
,    O
but    O
concludes    O
that    O
it    O
was    O
actually    O
Lot    O
who    O
abused    O
his    O
daughters    O
,    O
and    O
this    O
was    O
covered    O
up    O
by    O
the    O
biblical    O
narrators    O
.    O

Garret    O
awoke    O
,    O
but    O
blacked    O
out    O
several    O
times    O
during    O
2    O
days    O
of    O
torture    O
and    O
date    B-Sedative104166553
rape    I-Sedative104166553
drugs    I-Sedative104166553
.    O

One    O
of    O
Tracy    O
's    O
biggest    O
legislative    O
accomplishments    O
was    O
his    O
placing    O
the    O
Hoffman    O
-    O
LaRoche    O
drug    O
Rohypnol    O
-    O
known    O
clinically    O
as    O
flunitrazepam    B-Sedative104166553
and    O
commonly    O
as    O
"    O
roofies    O
"    O
-    O
in    O
Schedule    O
I    O
of    O
the    O
state    O
statutes    O
,    O
effectively    O
banning    O
the    O
date    B-Sedative104166553
rape    I-Sedative104166553
drug    I-Sedative104166553
in    O
Florida    O
with    O
severe    O
penalties    O
for    O
its    O
possession    O
and    O
use    O
.    O

:    O
QN05CD90    O
Climazolam    B-Sedative104166553

A    O
combination    O
of    O
amobarbital    O
and    O
secobarbital    O
(    O
called    O
Tuinal    B-Sedative104166553
)    O
is    O
also    O
highly    O
used    O
.    O

Parsons    O
had    O
taken    O
the    O
band    O
to    O
designer    O
Nudie    O
Cohn    O
to    O
have    O
custom    O
sequin    O
suits    O
made    O
for    O
all    O
the    O
band    O
members    O
especially    O
for    O
the    O
photo    O
shoot    O
,    O
but    O
Parsons    O
'    O
was    O
most    O
unusual    O
,    O
featuring    O
a    O
naked    O
woman    O
(    O
rendered    O
as    O
an    O
old    O
-    O
school    O
sailor    O
's    O
tattoo    O
on    O
each    O
lapel    O
)    O
,    O
red    O
poppies    O
on    O
the    O
shoulders    O
,    O
deep    O
-    O
green    O
marijuana    O
leaves    O
on    O
the    O
front    O
,    O
and    O
embroidered    O
Seconal    O
and    O
Tuinal    B-Sedative104166553
pills    O
scattered    O
elsewhere    O
.    O

Flucindole    B-Sedative104166553

Cyclopyrrolones    B-Sedative104166553
are    O
a    O
family    O
of    O
hypnotic    O
and    O
anxiolytic    O
nonbenzodiazepine    B-Sedative104166553
drugs    O
with    O
similar    O
pharmacological    O
profiles    O
to    O
the    O
benzodiazepine    O
derivatives    O
.    O

Use    O
of    O
tapentadol    O
with    O
alcohol    O
or    O
other    O
sedatives    O
such    O
as    O
benzodiazepines    O
,    O
barbiturates    O
,    O
nonbenzodiazepines    B-Sedative104166553
,    O
phenothiazines    O
,    O
and    O
other    O
opiates    O
may    O
result    O
in    O
increased    O
impairment    O
,    O
sedation    O
,    O
respiratory    O
depression    O
,    O
and    O
death    O
.    O

Saripidem    O
has    O
a    O
similar    O
pharmacological    O
profile    O
to    O
the    O
benzodiazepine    O
family    O
of    O
drugs    O
including    O
sedative    O
and    O
anxiolytic    O
properties    O
,    O
but    O
its    O
chemical    O
structure    O
is    O
quite    O
different    O
from    O
that    O
of    O
the    O
benzodiazepine    O
drugs    O
,    O
and    O
saripidem    O
is    O
described    O
as    O
a    O
nonbenzodiazepine    B-Sedative104166553
.    O

It    O
is    O
one    O
of    O
a    O
relatively    O
recently    O
developed    O
class    O
of    O
medicines    O
known    O
as    O
the    O
nonbenzodiazepine    B-Sedative104166553
,    O
which    O
have    O
similar    O
effects    O
to    O
the    O
older    O
benzodiazepine    O
group    O
,    O
but    O
with    O
quite    O
different    O
chemical    O
structures    O
.    O

Nonbenzodiazepine    B-Sedative104166553

Lorediplon    O
(    O
INN    O
)    O
is    O
a    O
nonbenzodiazepine    B-Sedative104166553
of    O
the    O
pyrazolopyrimidine    O
family    O
that    O
is    O
being    O
pursued    O
as    O
a    O
treatment    O
for    O
insomnia    O
but    O
has    O
not    O
completed    O
development    O
.    O

Loprazolam    O
,    O
similar    O
to    O
other    O
benzodiazepines    O
and    O
nonbenzodiazepine    B-Sedative104166553
hypnotic    O
drugs    O
causes    O
impairments    O
in    O
body    O
balance    O
and    O
standing    O
steadiness    O
in    O
individuals    O
who    O
wake    O
up    O
at    O
night    O
or    O
the    O
next    O
morning    O
.    O

Divaplon    O
(    O
RU-32698    O
)    O
is    O
a    O
nonbenzodiazepine    B-Sedative104166553
,    O
anxiolytic    O
and    O
anticonvulsant    O
drug    O
from    O
the    O
pyrazolopyrimidine    O
family    O
of    O
drugs    O
.    O

There    O
is    O
cross    O
tolerance    O
between    O
alcohol    O
,    O
the    O
benzodiazepines    O
,    O
the    O
barbiturates    O
,    O
the    O
nonbenzodiazepine    B-Sedative104166553
drugs    O
,    O
and    O
corticosteroids    O
,    O
which    O
all    O
act    O
by    O
enhancing    O
the    O
GABAA    O
receptor    O
's    O
function    O
via    O
modulating    O
the    O
chloride    O
ion    O
channel    O
function    O
of    O
the    O
GABAA    O
receptor    O
.    O

These    O
include    O
the    O
nonbenzodiazepine    B-Sedative104166553
Z-drugs    B-Sedative104166553
,    O
which    O
have    O
a    O
similar    O
mechanism    O
of    O
action    O
.    O

The    O
authors    O
also    O
warned    O
of    O
the    O
similarities    O
in    O
pharmacology    O
and    O
mechanism    O
of    O
action    O
of    O
the    O
newer    O
nonbenzodiazepine    B-Sedative104166553
Z    B-Sedative104166553
drugs    I-Sedative104166553
.    O

Compared    O
with    O
the    O
benzodiazepines    O
including    O
estazolam    O
,    O
the    O
nonbenzodiazepine    B-Sedative104166553
sedative    O
-    O
hypnotics    O
appeared    O
to    O
offer    O
few    O
,    O
if    O
any    O
,    O
significant    O
clinical    O
advantages    O
in    O
efficacy    O
or    O
tolerability    O
in    O
elderly    O
persons    O
.    O

Revospirone    B-Sedative104166553
-    O
anxiolytic    O

Fluotracen    B-Sedative104166553
(    O
SKF-28,175    B-Sedative104166553
)    O
is    O
a    O
tricyclic    O
drug    O
which    O
possesses    O
dual    O
antidepressant    O
and    O
antipsychotic    O
activity    O
.    O

Perathiepin    B-Sedative104166553

lormetazepam    B-Sedative104166553

Benzodiazepines    O
with    O
a    O
half    O
-    O
life    O
of    O
less    O
than    O
24    O
hours    O
include    O
alprazolam    O
,    O
bromazepam    O
,    O
brotizolam    O
,    O
flunitrazepam    B-Sedative104166553
,    O
loprazolam    B-Sedative104166553
,    O
lorazepam    O
,    O
lormetazepam    B-Sedative104166553
,    O
midazolam    O
,    O
nitrazepam    O
,    O
oxazepam    O
,    O
and    O
temazepam    O
.    O

Plato    O
went    O
to    O
lie    O
down    O
inside    O
her    O
Winnebago    O
motor    O
home    O
parked    O
outside    O
the    O
house    O
,    O
where    O
she    O
died    O
of    O
an    O
overdose    O
of    O
the    O
painkiller    O
Lortab    O
and    O
the    O
muscle    O
-    O
relaxant    O
Soma    B-Sedative104166553
.    O

Agonists    O
/    O
positive    O
allosteric    O
modulators    O
:    O
alcohol    O
(    O
ethanol    O
)    O
,    O
barbiturates    O
,    O
benzodiazepines    O
,    O
carisoprodol    B-Sedative104166553
,    O
chloral    O
hydrate    O
,    O
etaqualone    B-Sedative104166553
,    O
etomidate    O
,    O
glutethimide    O
,    O
kava    O
,    O
methaqualone    O
,    O
muscimol    O
,    O
neuroactive    O
steroids    O
,    O
z-drug    B-Sedative104166553
,    O
propofol    O
,    O
skullcap    O
,    O
valerian    O
,    O
theanine    O
,    O
volatile    O
/    O
inhaled    O
anaesthetics    O
.    O

carisoprodol    B-Sedative104166553
(    O
muscle    O
relaxant    O
)    O

Muscle    O
relaxants    O
-    O
carisoprodol    B-Sedative104166553
/    O
aspirin    O

This    O
can    O
result    O
in    O
fatal    O
overdoses    O
from    O
drugs    O
such    O
as    O
codeine    O
,    O
tramadol    O
,    O
and    O
carisoprodol    B-Sedative104166553
,    O
which    O
become    O
considerably    O
more    O
potent    O
after    O
being    O
metabolized    O
by    O
CYP    O
enzymes    O
.    O

Other    O
agents    O
directly    O
potentiate    O
the    O
effects    O
of    O
analgesics    O
,    O
such    O
as    O
using    O
hydroxyzine    O
,    O
promethazine    O
,    O
carisoprodol    B-Sedative104166553
,    O
or    O
tripelennamine    O
to    O
increase    O
the    O
pain    O
-    O
killing    O
ability    O
of    O
a    O
given    O
dose    O
of    O
opioid    O
analgesic    O
.    O

Alcohol    O
may    O
be    O
substituted    O
by    O
benzodiazepines    O
,    O
such    O
as    O
clonazepam    B-Sedative104166553
,    O
which    O
work    O
through    O
the    O
same    O
mechanism    O
.    O

Benzodiazepines    O
such    O
as    O
clonazepam    B-Sedative104166553
improve    O
tremors    O
caused    O
by    O
the    O
myoclonus    O
aspect    O
of    O
this    O
syndrome    O
by    O
binding    O
allosterically    O
to    O
GABAA    O
ionotropic    O
receptors    O
,    O
causing    O
an    O
influx    O
of    O
chloride    O
ions    O
that    O
produce    O
an    O
inhibitory    O
effect    O
that    O
can    O
calm    O
myoclonic    O
jerks    O
.    O

Buspirone    O
,    O
quetiapine    O
and    O
pregabalin    O
are    O
second    O
line    O
treatments    O
for    O
people    O
who    O
do    O
not    O
respond    O
to    O
SSRIs    O
or    O
SNRIs    O
;    O
there    O
is    O
also    O
evidence    O
that    O
benzodiazepines    O
including    O
diazepam    O
and    O
clonazepam    B-Sedative104166553
are    O
effective    O
but    O
have    O
fallen    O
out    O
of    O
favor    O
due    O
to    O
the    O
risk    O
of    O
dependence    O
and    O
abuse    O
.    O

Clonazepam    B-Sedative104166553
(    O
Klonopin    O
)    O
,    O
anxiolytic    O

Other    O
drugs    O
commonly    O
used    O
to    O
treat    O
PTE    O
include    O
clonazepam    B-Sedative104166553
,    O
phenobarbitol    O
,    O
primidone    O
,    O
gabapentin    O
,    O
and    O
ethosuximide    O
.    O

While    O
in    O
the    O
hospital    O
for    O
treatment    O
,    O
Green    O
was    O
diagnosed    O
with    O
"    O
major    O
bipolar    O
depression    O
with    O
suicidal    O
impulses    O
"    O
and    O
placed    O
on    O
Prozac    O
,    O
Tranxene    B-Sedative104166553
,    O
and    O
Klonopin    B-Sedative104166553
.    O

Diazepam    O
and    O
clonazepam    B-Sedative104166553
â    O
to    O
decrease    O
intensity    O
of    O
spasms    O

Other    O
classical    O
benzodiazepines    O
include    O
chlordiazepoxide    O
,    O
clonazepam    B-Sedative104166553
,    O
lorazepam    O
,    O
oxazepam    O
,    O
nitrazepam    O
,    O
temazepam    O
,    O
flurazepam    O
,    O
bromazepam    O
,    O
and    O
clorazepate    B-Sedative104166553
.    O

Benzodiazepines    O
with    O
a    O
half    O
-    O
life    O
of    O
more    O
than    O
24    O
hours    O
include    O
chlordiazepoxide    O
,    O
diazepam    O
,    O
clobazam    B-Sedative104166553
,    O
clonazepam    B-Sedative104166553
,    O
chlorazepinic    O
acid    O
,    O
ketazolam    B-Sedative104166553
,    O
medazepam    B-Sedative104166553
,    O
nordazepam    B-Sedative104166553
,    O
and    O
prazepam    B-Sedative104166553
.    O

Barbiturates    O
are    O
also    O
used    O
to    O
alleviate    O
the    O
adverse    O
or    O
withdrawal    O
effects    O
of    O
illicit    O
drug    O
use    O
,    O
in    O
a    O
manner    O
similar    O
to    O
long    O
-    O
acting    O
benzodiazepines    O
such    O
as    O
diazepam    O
and    O
clonazepam    B-Sedative104166553
.    O

It    O
was    O
the    O
first    O
album    O
she    O
released    O
after    O
her    O
much    O
publicized    O
departure    O
from    O
Fleetwood    O
Mac    O
,    O
and    O
during    O
the    O
tail    O
end    O
of    O
her    O
7-year    O
-    O
long    O
dependency    O
on    O
the    O
prescription    O
medication    O
Klonopin    B-Sedative104166553
.    O

This    O
disorder    O
is    O
usually    O
acquired    O
in    O
one    O
of    O
four    O
ways    O
:    O
One    O
cause    O
is    O
benzodiazepine    O
drugs    O
such    O
as    O
;    O
midazolam    O
,    O
flunitrazepam    B-Sedative104166553
,    O
lorazepam    O
,    O
temazepam    O
,    O
nitrazepam    O
,    O
triazolam    O
,    O
clonazepam    B-Sedative104166553
,    O
alprazolam    O
,    O
diazepam    O
,    O
and    O
nimetazepam    O
;    O
all    O
of    O
which    O
are    O
known    O
to    O
have    O
powerful    O
amnesic    O
effects    O
.    O

Seizure    O
frequency    O
can    O
be    O
regulated    O
by    O
the    O
use    O
of    O
drugs    O
such    O
as    O
Clonazepam    B-Sedative104166553
(    O
or    O
other    O
benzodiazepines    O
)    O
and    O
Sodium    O
Valproate    O
.    O

Benzodiazepines    O
more    O
likely    O
to    O
cause    O
euphoria    O
are    O
flunitrazepam    B-Sedative104166553
,    O
alprazolam    O
and    O
clonazepam    B-Sedative104166553
.    O

In    O
2004    O
,    O
two    O
North    O
Korean    O
embassy    O
employees    O
were    O
caught    O
smuggling    O
150,000    O
tablets    O
of    O
Clonazepam    B-Sedative104166553
in    O
Egypt    O
,    O
and    O
in    O
that    O
same    O
year    O
,    O
embassy    O
employees    O
from    O
Bulgaria    O
were    O
arrested    O
in    O
Turkey    O
in    O
possession    O
of    O
over    O
500,000    O
tablets    O
of    O
Captagon    O
(    O
the    O
brand    O
name    O
for    O
the    O
synthetic    O
stimulant    O
fenethylline    O
,    O
or    O
phenethylline    O
)    O
,    O
with    O
an    O
estimated    O
street    O
value    O
of    O
$    O
7    O
million    O
.    O

The    O
rise    O
of    O
gas    O
anesthesia    O
using    O
nitrous    O
oxide    O
,    O
improved    O
equipment    O
for    O
administering    O
anesthetics    O
and    O
the    O
discovery    O
of    O
hexobarbital    B-Sedative104166553
in    O
1932    O
led    O
to    O
the    O
gradual    O
decline    O
of    O
chloroform    O
narcosis    O
.    O

hexobarbital    B-Sedative104166553

1866    O
â    O
Karl    O
of    O
Hohenzollern    O
-    O
Sigmaringen    O
is    O
crowned    O
the    O
Ruling    B-Sedative104166553
Prince    I-Sedative104166553
of    O
the    O
United    O
Principalities    O
of    O
Romania    O
.    O

Medetomidine    B-Sedative104166553

Premazepam    B-Sedative104166553

Polybutyrate    O
(    O
short    O
for    O
polybutyrate    O
adipate    O
terephthalate    O
,    O
or    O
PBAT    O
)    O
is    O
a    O
biodegradable    O
random    O
copolymer    O
,    O
specifically    O
a    O
copolyester    O
of    O
adipic    O
acid    O
,    O
1,4-butanediol    B-Sedative104166553
and    O
dimethyl    O
terephthalate    O
.    O

PBAT    O
is    O
synthesized    O
through    O
the    O
polymers    O
butylene    O
adipate    O
(    O
polymer    O
of    O
1,4-butanediol    B-Sedative104166553
and    O
adipic    O
acid    O
)    O
and    O
dimethyl    O
terephthalate    O
(    O
DMT    O
)    O
with    O
1,4-butanediol    O
.    O

The    O
polyester    O
of    O
adipic    O
acid    O
is    O
synthesized    O
using    O
1,4-butanediol    B-Sedative104166553
.    O

The    O
polyester    O
of    O
DMT    O
is    O
generated    O
using    O
1,4-butanediol    B-Sedative104166553
.    O

Î³-Hydroxybutyraldehyde    O
,    O
also    O
referred    O
to    O
as    O
GHBAL    O
,    O
Î³-hydroxybutaldehyde    O
or    O
Î³-hydroxybutanal    O
,    O
is    O
a    O
chemical    O
intermediate    O
in    O
the    O
biosynthesis    O
of    O
the    O
neurotransmitter    O
Î³-hydroxybutyric    B-Sedative104166553
acid    I-Sedative104166553
(    O
GHB    O
)    O
from    O
1,4-butanediol    B-Sedative104166553
(    O
1,4-BD    O
)    O
.    O

1,4-Butanediol    B-Sedative104166553

Clorotepine    B-Sedative104166553

medazepam    B-Sedative104166553

Benzodiazepines    O
with    O
a    O
half    O
-    O
life    O
of    O
more    O
than    O
24    O
hours    O
include    O
chlordiazepoxide    O
,    O
diazepam    O
,    O
clobazam    B-Sedative104166553
,    O
clonazepam    B-Sedative104166553
,    O
chlorazepinic    O
acid    O
,    O
ketazolam    B-Sedative104166553
,    O
medazepam    B-Sedative104166553
,    O
nordazepam    B-Sedative104166553
,    O
and    O
prazepam    B-Sedative104166553
.    O

Flubromazepam    B-Sedative104166553
is    O
a    O
benzodiazepine    O
derivative    O
which    O
was    O
first    O
synthesized    O
in    O
1960    O
,    O
but    O
was    O
never    O
marketed    O
and    O
did    O
not    O
receive    O
any    O
further    O
attention    O
or    O
study    O
until    O
late    O
2012    O
when    O
it    O
appeared    O
on    O
the    O
grey    O
market    O
as    O
a    O
novel    O
designer    O
drug    O
.    O

White    O
sticks    O
represent    O
the    O
carbon    O
atoms    O
of    O
the    O
benzodiazepine    O
diazepam    O
,    O
while    O
green    O
represents    O
carbon    O
atoms    O
of    O
the    O
nonbenzodiazepine    O
CGS-9896    B-Sedative104166553
.    O

Thiobarbital    B-Sedative104166553
is    O
a    O
drug    O
which    O
is    O
a    O
barbiturate    O
derivative    O
.    O

:    O
N05CC04    O
Dichloralphenazone    B-Sedative104166553

Thiamylal    B-Sedative104166553
(    O
trade    O
name    O
:    O
Surital    O
)    O

Lufuradom    B-Sedative104166553
(    O
INN    O
)    O
is    O
a    O
drug    O
and    O
benzodiazepine    O
derivative    O
which    O
,    O
unlike    O
other    O
benzodiazepines    O
,    O
is    O
described    O
as    O
an    O
analgesic    O
.    O

Minitran    B-Sedative104166553

Vortioxetine    B-Sedative104166553
(    O
Ki    O
=    O
54    O
nM    O
)    O

Vortioxetine    B-Sedative104166553
(    O
Ki    O
=    O
3.7    O
nM    O
)    O

Vortioxetine    B-Sedative104166553
(    O
Ki    O
=    O
19    O
nM    O
)    O

Vortioxetine    B-Sedative104166553

Propylbarbital    B-Sedative104166553
(    O
Propal    B-Sedative104166553
,    O
Propanal    B-Sedative104166553
,    O
Proponal    B-Sedative104166553
)    O
,    O
also    O
known    O
as    O
5,5-dipropylbarbituric    B-Sedative104166553
acid    I-Sedative104166553
,    O
is    O
a    O
barbiturate    O
derivative    O
used    O
as    O
a    O
hypnotic    O
drug    O
.    O

Fletazepam    O
is    O
most    O
closely    O
related    O
to    O
other    O
"    O
N    O
"-    O
trifluoroethyl    O
substituted    O
benzodiazepines    O
such    O
as    O
halazepam    B-Sedative104166553
and    O
quazepam    B-Sedative104166553
.    O

The    O
executive    O
producers    O
are    O
Jou    O
Vicky    O
Ramirez    O
,    O
Camilo    O
Guanes    O
and    O
Rocio    O
Galiano    O
,    O
while    O
Oniria    B-Sedative104166553
is    O
the    O
advertising    O
agency    O
of    O
the    O
movie    O
.    O

SL-164    B-Sedative104166553

4-Iodopropofol    B-Sedative104166553
is    O
a    O
drug    O
derived    O
from    O
the    O
commonly    O
used    O
sedative    O
anaesthetic    O
agent    O
,    O
propofol    O
.    O

sulazepam    B-Sedative104166553
(    O
INN    O
)    O

Clobazam    B-Sedative104166553

#    O
Clobazam    B-Sedative104166553

clobazam    B-Sedative104166553

Benzodiazepines    O
with    O
a    O
half    O
-    O
life    O
of    O
more    O
than    O
24    O
hours    O
include    O
chlordiazepoxide    O
,    O
diazepam    O
,    O
clobazam    B-Sedative104166553
,    O
clonazepam    B-Sedative104166553
,    O
chlorazepinic    O
acid    O
,    O
ketazolam    B-Sedative104166553
,    O
medazepam    B-Sedative104166553
,    O
nordazepam    B-Sedative104166553
,    O
and    O
prazepam    B-Sedative104166553
.    O

Indiplon    B-Sedative104166553
for    O
insomnia    O
,    O
licensed    O
from    O
Wyeth    O
in    O
1998    O
,    O
which    O
it    O
licensed    O
to    O
Neurocrine    O
Biosciences    O
in    O
1998    O
.    O

Tifluadom    B-Sedative104166553

FGIN-127    B-Sedative104166553

QH-ii-066    B-Sedative104166553

Pipequaline    B-Sedative104166553

Healy    O
allegedly    O
encountered    O
ghost    O
writing    O
involving    O
Wyeth    O
's    O
SNRI    O
Effexor    B-Sedative104166553
.    O

As    O
of    O
2013    O
,    O
the    O
10    O
most    O
prescribed    O
psychiatric    O
drugs    O
by    O
number    O
of    O
prescriptions    O
were    O
alprazolam    O
,    O
sertraline    O
,    O
citalopram    B-Sedative104166553
,    O
fluoxetine    O
,    O
lorazepam    O
,    O
trazodone    O
,    O
escitalopram    B-Sedative104166553
,    O
duloxetine    O
,    O
bupropion    O
XL    O
,    O
and    O
venlafaxine    B-Sedative104166553
XR    I-Sedative104166553
.    O

Venlafaxine    B-Sedative104166553
(    O
Effexor    O
)    O
,    O
SNRI    O

Venlafaxine    B-Sedative104166553
(    O
Effexor    O
)    O
may    O
be    O
moderately    O
more    O
effective    O
than    O
SSRIs    O
;    O
however    O
,    O
it    O
is    O
not    O
recommended    O
as    O
a    O
first    O
-    O
line    O
treatment    O
because    O
of    O
the    O
higher    O
rate    O
of    O
side    O
effects    O
,    O
and    O
its    O
use    O
is    O
specifically    O
discouraged    O
in    O
children    O
and    O
adolescents    O
.    O

Venlafaxine    B-Sedative104166553
/    O
quetiapine    O
?    O

The    O
following    O
list    O
shows    O
the    O
rates    O
of    O
adverse    O
symptoms    O
seen    O
in    O
people    O
taking    O
venlafaxine    B-Sedative104166553
.    O

Mirtazapine    O
in    O
combination    O
with    O
an    O
SSRI    O
,    O
,    O
or    O
TCA    O
as    O
an    O
augmentation    O
strategy    O
is    O
considered    O
to    O
be    O
relatively    O
safe    O
and    O
is    O
often    O
employed    O
therapeutically    O
,    O
with    O
a    O
combination    O
of    O
venlafaxine    B-Sedative104166553
and    O
mirtazapine    O
,    O
sometimes    O
referred    O
to    O
as    O
"    O
California    O
rocket    O
fuel    O
"    O
.    O

The    O
rate    O
of    O
withdrawal    O
symptoms    O
in    O
young    O
people    O
may    O
be    O
higher    O
with    O
paroxetine    O
and    O
venlafaxine    B-Sedative104166553
than    O
other    O
SSRIs    O
and    O
SNRIs    O
.    O

Comparative    O
efficacy    O
of    O
paroxetine    O
is    O
equivalent    O
to    O
that    O
of    O
clomipramine    O
and    O
venlafaxine    B-Sedative104166553
.    O

Tramadol    O
is    O
structurally    O
closer    O
to    O
venlafaxine    B-Sedative104166553
than    O
to    O
codeine    O
and    O
delivers    O
analgesia    O
by    O
not    O
only    O
delivering    O
"    O
opioid    O
-    O
like    O
"    O
effects    O
(    O
through    O
mild    O
agonism    O
of    O
the    O
mu    O
receptor    O
)    O
but    O
also    O
by    O
acting    O
as    O
a    O
weak    O
but    O
fast    O
-    O
acting    O
serotonin    O
releasing    O
agent    O
and    O
norepinephrine    O
reuptake    O
inhibitor    O
.    O

Commonly    O
used    O
ones    O
are    O
venlafaxine    B-Sedative104166553
,    O
nefazadone    O
,    O
bupropion    O
,    O
mirtazapine    O
and    O
trazodone    O
.    O

Level    O
four    O
consisted    O
of    O
the    O
monoamine    O
oxidase    O
inhibitor    O
tranylcypromine    O
or    O
a    O
combination    O
of    O
venlafaxine    B-Sedative104166553
and    O
mirtazapine    O
.    O

Venlafaxine    B-Sedative104166553

"    O
Lagochilus    B-Sedative104166553
inebrians    I-Sedative104166553
"    O
(    O
spelled    O
"    O
Lagoehilus    O
inebrians    O
"    O
in    O
the    O
bill    O
)    O

lorpiprazole    B-Sedative104166553
(    O
INN    O
)    O

Another    O
was    O
Dexamyl    B-Sedative104166553
tablets    O
.    O

Dexamyl    B-Sedative104166553

Several    O
popular    O
products    O
sold    O
by    O
SKF    O
contained    O
amphetamine    O
including    O
Benzedrine    O
pills    O
and    O
inhalers    O
,    O
Dexedrine    O
pills    O
,    O
and    O
Dexamyl    B-Sedative104166553
tablets    O
.    O

As    O
institute    O
president    O
,    O
Boyd    O
chaired    O
the    O
Board    O
of    O
Directors    O
of    O
the    O
Georgia    B-Sedative104166553
Tech    I-Sedative104166553
Athletic    I-Sedative104166553
Association    I-Sedative104166553
,    O
which    O
had    O
been    O
suffering    O
both    O
in    O
win    O
percentage    O
and    O
in    O
finances    O
.    O

While    O
it    O
was    O
partially    O
funded    O
by    O
the    O
state    O
of    O
Georgia    O
,    O
a    O
large    O
part    O
of    O
the    O
funding    O
for    O
Brittain    O
Dining    O
Hall    O
came    O
from    O
the    O
Athletic    B-Sedative104166553
Association    I-Sedative104166553
and    O
the    O
Georgia    O
Tech    O
Expansion    O
Fund    O
.    O

ciclindole    B-Sedative104166553
(    O
INN    O
)    O

:    O
N05AH06    O
Clotiapine    B-Sedative104166553

Piquindone    B-Sedative104166553

Etaqualone    B-Sedative104166553

Etaqualone    B-Sedative104166553

Telenzepine    B-Sedative104166553
is    O
atropisomeric    O
,    O
in    O
other    O
words    O
the    O
molecule    O
has    O
a    O
stereogenic    O
Câ    O

Oxomemazine/guaifenesin    B-Sedative104166553

#    O
Tetrazepam    B-Sedative104166553

tetrazepam    B-Sedative104166553

Ro5-4864    B-Sedative104166553
-    O
original    O
ligand    O
with    O
which    O
TSPO    O
receptor    O
was    O
characterised    O
,    O
now    O
less    O
used    O
due    O
to    O
inter    O
-    O
species    O
differences    O
in    O
binding    O
affinity    O
.    O

Kavain    B-Sedative104166553
is    O
the    O
main    O
kavalactone    B-Sedative104166553
found    O
mostly    O
in    O
the    O
roots    O
of    O
the    O
kava    O
plant    O
.    O

Febarbamate    B-Sedative104166553

Dexmedetomidine    B-Sedative104166553
and    O
atypical    B-Sedative104166553
antipsychotic    I-Sedative104166553
agents    I-Sedative104166553
are    O
other    O
premedications    O
which    O
are    O
used    O
particularly    O
in    O
very    O
uncooperative    O
children    O
.    O

Dexmedetomidine    B-Sedative104166553

:*    O
Dexdor    O
(    O
"    O
dexmedetomidine    B-Sedative104166553
"    O
)    O

dexmedetomidine    B-Sedative104166553
(    O
sedative    O
)    O

Piperidione    B-Sedative104166553
(    O
trade    O
name    O
Sedulon    B-Sedative104166553
)    O
is    O
a    O
sedative    O
drug    O
,    O
structurally    O
related    O
to    O
methyprylon    B-Sedative104166553
and    O
pyrithyldione    B-Sedative104166553
.    O

Methylmethaqualone    B-Sedative104166553

Cyclopentobarbital    B-Sedative104166553

Desmethylclozapine    B-Sedative104166553

Tetrabamate    B-Sedative104166553
(    O
Atrium    B-Sedative104166553
,    O
G    B-Sedative104166553
Tril    I-Sedative104166553
,    O
Sevrium    B-Sedative104166553
)    O
is    O
a    O
combination    O
drug    O
formulation    O
of    O
febarbamate    B-Sedative104166553
,    O
difebarbamate    B-Sedative104166553
,    O
and    O
phenobarbital    O
which    O
was    O
marketed    O
in    O
France    O
and    O
Spain    O
and    O
was    O
used    O
to    O
treat    O
anxiety    O
and    O
alcohol    O
withdrawal    O
-    O
associated    O
muscle    O
tremors    O
,    O
agitation    O
,    O
and    O
depression    O
.    O

The    O
amino    O
acid    O
tryptophan    O
is    O
converted    O
into    O
5-hydroxytryptophan    B-Sedative104166553
(    O
5-HTP    O
)    O
which    O
is    O
subsequently    O
converted    O
into    O
the    O
neurotransmitter    O
serotonin    O
.    O

Amine    O
Precursor    O
Uptake    O
-    O
for    O
high    O
uptake    O
of    O
amine    O
precursors    O
including    O
5-hydroxytryptophan    O
(    O
5-HTP    B-Sedative104166553
)    O
and    O
dihydroxyphenylalanine    O
(    O
DOPA    O
)    O
.    O

Treatment    O
of    O
THB    O
deficiencies    O
consists    O
of    O
THB    O
supplementation    O
(    O
2â20    O
mg    O
/    O
kg    O
per    O
day    O
)    O
or    O
diet    O
to    O
control    O
blood    O
phenylalanine    O
concentration    O
and    O
replacement    O
therapy    O
with    O
neurotransmitters    O
precursors    O
(    O
L    O
-    O
DOPA    O
and    O
5-HTP    B-Sedative104166553
)    O
and    O
supplements    O
of    O
folinic    O
acid    O
in    O
DHPR    O
deficiency    O
.    O

The    O
seeds    O
of    O
the    O
plant    O
are    O
used    O
as    O
a    O
herbal    O
supplement    O
for    O
their    O
5-hydroxytryptophan    B-Sedative104166553
(    O
5-HTP    O
)    O
content    O
.    O

Velvet    O
bean    O
(    O
"    O
M.    O
pruriens    O
"    O
)    O
is    O
one    O
of    O
the    O
most    O
important    O
sources    O
of    O
L    O
-    O
dopa    O
,    O
a    O
common    O
component    O
of    O
nootropics    O
(    O
"    O
smart    O
drugs    O
"    O
)    O
;    O
it    O
also    O
contains    O
serotonin    O
,    O
5-HTP    B-Sedative104166553
,    O
nicotine    O
,    O
and    O
some    O
decidedly    O
psychoactive    O
compounds    O
(    O
see    O
below    O
)    O
.    O

Tryptophan    O
and    O
5-hydroxy-tryptophan    B-Sedative104166553
,    O
for    O
instance    O
,    O
can    O
be    O
used    O
to    O
help    O
the    O
body    O
replenish    O
serotonin    O
levels    O
in    O
the    O
brain    O
after    O
the    O
use    O
of    O
MDMA    O
,    O
and    O
vitamin    O
supplements    O
are    O
appropriate    O
for    O
users    O
of    O
stimulants    O
such    O
as    O
amphetamine    O
.    O

mCPP    O
is    O
a    O
metabolite    O
of    O
a    O
variety    O
of    O
other    O
piperazine    O
drugs    O
including    O
trazodone    O
,    O
nefazodone    O
,    O
etoperidone    O
,    O
enpiprazole    B-Sedative104166553
,    O
mepiprazole    O
,    O
cloperidone    O
,    O
and    O
peraclopone    O
.    O

Demoxepam    B-Sedative104166553

On    O
Friday    O
,    O
January    O
06    O
,    O
2017    O
Representative    O
Jacobs    O
filed    O
Bill    O
HB    O
183    O
in    O
The    O
Florida    O
House    O
of    O
Representatives    O
which    O
,    O
if    O
passed    O
and    O
signed    O
into    O
law    O
,    O
would    O
effectively    O
schedule    O
kratom    B-Sedative104166553
as    O
a    O
controlled    O
substance    O
.    O

The    O
drugs    O
involved    O
range    O
from    O
the    O
traditional    O
,    O
kratom    B-Sedative104166553
,    O
to    O
ya    O
ba    O
,    O
opium    O
from    O
Myanmar    O
,    O
and    O
local    O
herbal    O
medicines    O
.    O

Mitragyna    B-Sedative104166553
speciosa    I-Sedative104166553
(    O
kratom    O
)    O
indole    O
derivatives    O
:    O

Lofendazam    B-Sedative104166553
is    O
an    O
organic    O
molecule    O
which    O
is    O
a    O
benzodiazepine    O
derivative    O
.    O

Sedation    B-Sedative104166553
dentistry    I-Sedative104166553

Ocaperidone    B-Sedative104166553
(    O
also    O
R    B-Sedative104166553
79598    I-Sedative104166553
)    O
is    O
a    O
benzisoxazole    O
antipsychotic    O
.    O

Georgia    B-Sedative104166553
Tech    I-Sedative104166553
Yellow    I-Sedative104166553
Jackets    I-Sedative104166553

On    O
May    O
15    O
,    O
2012    O
,    O
Messer    O
was    O
named    O
the    O
new    O
Associate    O
Head    O
Coach    O
of    O
the    O
Georgia    B-Sedative104166553
Tech    I-Sedative104166553
Yellow    I-Sedative104166553
Jackets    I-Sedative104166553
.    O

The    O
demolition    O
of    O
the    O
Omni    O
forced    O
the    O
Hawks    O
to    O
split    O
the    O
1997    O
-    O
98    O
and    O
1999    O
seasons    O
between    O
Alexander    O
Memorial    O
Coliseum    O
at    O
Georgia    B-Sedative104166553
Tech    I-Sedative104166553
,    O
their    O
first    O
home    O
in    O
Atlanta    O
,    O
and    O
the    O
Georgia    O
Dome    O
.    O

Matt    O
Kuchar    O
,    O
a    O
19-year    O
-    O
old    O
sophomore    O
at    O
Georgia    B-Sedative104166553
Tech    I-Sedative104166553
,    O
was    O
the    O
low    O
amateur    O
at    O
even    O
-    O
par    O
288    O
and    O
tied    O
for    O
21st    O
place    O
.    O

The    O
Georgia    O
Tech    O
â    O
Tulane    O
football    O
rivalry    O
is    O
an    O
American    O
college    O
football    O
rivalry    O
between    O
the    O
Georgia    B-Sedative104166553
Tech    I-Sedative104166553
Yellow    I-Sedative104166553
Jackets    I-Sedative104166553
and    O
Tulane    O
Green    O
Wave    O
.    O

After    O
committing    O
to    O
Georgia    B-Sedative104166553
Tech    I-Sedative104166553
,    O
Dwyer    O
got    O
plenty    O
of    O
playing    O
time    O
as    O
the    O
backup    O
running    O
back    O
to    O
senior    O
Tashard    O
Choice    O
.    O

Wes    O
Durham    O
â    O
radio    O
play    O
-    O
by    O
-    O
play    O
announcer    O
for    O
the    O
Georgia    O
Tech    O
Yellow    B-Sedative104166553
Jackets    I-Sedative104166553
and    O
the    O
Atlanta    O
Falcons    O

The    O
following    O
quarterbacks    O
were    O
the    O
leading    O
passer    O
for    O
the    O
Yellow    B-Sedative104166553
Jackets    I-Sedative104166553
each    O
season    O
since    O
joining    O
the    O
Atlantic    O
Coast    O
Conference    O
in    O
1979    O
.    O

Eddie    O
McAshan    O
,    O
quarterback    O
for    O
the    O
Yellow    B-Sedative104166553
Jackets    I-Sedative104166553
1970    O
-    O
1972    O
;    O
played    O
in    O
the    O
WFL    O
(    O
1974    O
-    O
1975    O
)    O
.    O

George    O
Morris    O
,    O
76    O
,    O
American    O
football    O
player    O
(    O
Georgia    B-Sedative104166553
Tech    I-Sedative104166553
,    O
San    O
Francisco    O
49ers    O
)    O
,    O
apparent    O
heart    O
attack    O
.    O

During    O
this    O
stretch    O
,    O
Winthrop    O
defeated    O
such    O
major    O
conference    O
programs    O
as    O
Georgia    B-Sedative104166553
Tech    I-Sedative104166553
,    O
Miami    O
,    O
Notre    O
Dame    O
,    O
Marquette    O
,    O
Mississippi    O
State    O
,    O
Providence    O
,    O
Missouri    O
,    O
Georgia    O
,    O
and    O
Clemson    O
.    O

During    O
his    O
senior    O
year    O
,    O
he    O
was    O
a    O
member    O
of    O
Georgia    O
Tech    O
's    O
famed    O
gridiron    O
squad    O
,    O
the    B-Sedative104166553
Yellow    I-Sedative104166553
Jackets    I-Sedative104166553
.    O

USC    O
Trojans    O
â    O
college    O
football    O
national    O
championship    O
shared    O
with    O
Georgia    B-Sedative104166553
Tech    I-Sedative104166553
Yellow    I-Sedative104166553
Jackets    I-Sedative104166553

Born    O
in    O
Valdosta    O
,    O
Georgia    O
,    O
Henry    O
attended    O
Georgia    O
Tech    O
in    O
Atlanta    O
on    O
a    O
football    O
scholarship    O
,    O
and    O
also    O
played    O
on    O
the    O
Yellow    B-Sedative104166553
Jackets    I-Sedative104166553
'    O
golf    O
team    O
.    O

Dews    O
played    O
baseball    O
and    O
basketball    O
for    O
the    O
Georgia    O
Tech    O
Yellow    B-Sedative104166553
Jackets    I-Sedative104166553
before    O
being    O
drafted    O
by    O
the    O
St.    O
Louis    O
Cardinals    O
.    O

This    O
was    O
the    O
first    O
time    O
that    O
the    O
Georgia    O
Tech    O
sports    O
teams    O
were    O
referred    O
to    O
as    O
the    O
Georgia    B-Sedative104166553
Tech    I-Sedative104166553
Yellow    I-Sedative104166553
Jackets    I-Sedative104166553
in    O
print    O
.    O

On    O
March    O
22    O
,    O
Osterman    O
recorded    O
her    O
118th    O
career    O
win    O
â    O
over    O
the    O
Georgia    B-Sedative104166553
Tech    I-Sedative104166553
Yellow    I-Sedative104166553
Jackets    I-Sedative104166553
â    O
to    O
tie    O
Jamie    O
Southern    O
for    O
10th    O
place    O
on    O
the    O
NCAA    O
all    O
-    O
time    O
list    O
.    O

These    O
colors    O
represented    O
the    O
two    O
college    O
rival    O
schools    O
in    O
the    O
state    O
of    O
Georgia    O
;    O
rival    O
schools    O
Georgia    B-Sedative104166553
Tech    I-Sedative104166553
Yellow    I-Sedative104166553
Jackets    I-Sedative104166553
(    O
White    O
and    O
Gold    O
)    O
and    O
the    O
Georgia    O
Bulldogs    O
(    O
Red    O
and    O
Black    O
)    O
.    O

Georgia    B-Sedative104166553
Tech    I-Sedative104166553
and    O
Auburn    O

Georgia    B-Sedative104166553
Tech    I-Sedative104166553
and    O
Alabama    O

Georgia    B-Sedative104166553
Tech    I-Sedative104166553
and    O
Tennessee    O

Georgia    B-Sedative104166553
Tech    I-Sedative104166553
Yellow    I-Sedative104166553
Jackets    I-Sedative104166553

The    O
Rebels    O
,    O
as    O
the    O
No    O
.    O
2    O
seed    O
in    O
the    O
regional    O
,    O
defeated    O
the    O
University    O
of    O
Denver    O
4    O
-    O
1    O
in    O
the    O
first    O
round    O
and    O
lost    O
to    O
host    O
Georgia    B-Sedative104166553
Tech    I-Sedative104166553
Yellow    I-Sedative104166553
Jackets    I-Sedative104166553
4    O
-    O
1    O
in    O
the    O
second    O
round    O
,    O
ending    O
the    O
Rebels    O
'    O
season    O
with    O
a    O
15    O
-    O
10    O
record    O
.    O

The    O
2002    O
squad    O
,    O
which    O
had    O
difficulty    O
opening    O
the    O
season    O
with    O
a    O
1    O
-    O
3    O
record    O
,    O
finished    O
strong    O
to    O
finish    O
the    O
regular    O
season    O
8    O
-    O
5    O
and    O
earning    O
another    O
bid    O
to    O
the    O
Silicon    O
Valley    O
Classic    O
against    O
Georgia    B-Sedative104166553
Tech    I-Sedative104166553
.    O

Georgia    B-Sedative104166553
Tech    I-Sedative104166553
Yellow    I-Sedative104166553
Jackets    I-Sedative104166553
of    O
Atlanta    O
,    O
Georgia    O

The    O
next    O
week    O
,    O
Miami    O
welcomed    O
the    O
triple    O
option    O
offense    O
of    O
the    O
#    O
14    O
Georgia    B-Sedative104166553
Tech    I-Sedative104166553
Yellow    I-Sedative104166553
Jackets    I-Sedative104166553
in    O
yet    O
another    O
ESPN    O
prime    O
-    O
time    O
game    O
.    O

Pivoxazepam    B-Sedative104166553
is    O
a    O
drug    O
which    O
is    O
a    O
benzodiazepine    O
derivative    O
.    O

Alentemol    B-Sedative104166553
(    O
INN    O
)    O
(    O
developmental    O
code    O
name    O
U-66444B    B-Sedative104166553
)    O
,    O
or    O
alentamol    B-Sedative104166553
,    O
is    O
a    O
selective    O
dopamine    O
autoreceptor    O
agonist    O
described    O
as    O
an    O
antipsychotic    O
,    O
which    O
was    O
never    O
marketed    O
.    O

mazapertine    B-Sedative104166553
(    O
INN    O
)    O

Zicronapine    B-Sedative104166553
(    O
,    O
previously    O
known    O
as    O
Lu    B-Sedative104166553
31-130    I-Sedative104166553
)    O
is    O
an    O
atypical    B-Sedative104166553
antipsychotic    I-Sedative104166553
medication    O
formerly    O
under    O
development    O
by    O
H.    O
Lundbeck    O
A    O
/    O
S.    O
In    O
phase    O
II    O
studies    O
zicronapine    O
showed    O
statistically    O
significant    O
separation    O
from    O
placebo    O
and    O
convincing    O
efficacy    O
and    O
safety    O
data    O
when    O
compared    O
to    O
olanzapine    B-Sedative104166553
.    O

#    O
Flunitrazepam    B-Sedative104166553

Schedule    O
III    O
includes    O
barbiturate    O
products    O
with    O
fast    O
or    O
average    O
effects    O
,    O
which    O
have    O
been    O
the    O
object    O
of    O
serious    O
abuse    O
even    O
though    O
useful    O
therapeutically    O
,    O
strongly    O
sedative    O
benzodiazepines    O
like    O
flunitrazepam    B-Sedative104166553
and    O
some    O
analgesics    O
like    O
buprenorphine    O
.    O

This    O
provision    O
,    O
which    O
calls    O
for    O
temporarily    O
placing    O
a    O
drug    O
under    O
federal    O
drug    O
control    O
in    O
the    O
event    O
the    O
Convention    O
requires    O
it    O
,    O
was    O
invoked    O
in    O
1984    O
with    O
Rohypnol    O
(    O
flunitrazepam    B-Sedative104166553
)    O
.    O

flunitrazepam    B-Sedative104166553

Contemporary    O
crime    O
including    O
date    O
rape    O
following    O
the    O
use    O
of    O
hypnotic    O
drugs    O
such    O
as    O
Flunitrazepam    B-Sedative104166553
show    O
that    O
little    O
has    O
changed    O
save    O
that    O
where    O
the    O
intended    O
offence    O
is    O
of    O
a    O
sexual    O
nature    O
,    O
separate    O
legislation    O
applies    O
(    O
see    O
Sexual    O
Offences    O
Act    O
2003    O
)    O
.    O

In    O
the    O
first    O
episode    O
,    O
Bo    O
saves    O
a    O
young    O
human    O
woman    O
,    O
Kenzi    O
,    O
from    O
a    O
rapist    O
who    O
had    O
surreptitiously    O
drugged    O
her    O
with    O
a    O
"    O
roofie    B-Sedative104166553
"    O
in    O
her    O
drink    O
.    O

Benzodiazepines    O
with    O
a    O
half    O
-    O
life    O
of    O
less    O
than    O
24    O
hours    O
include    O
alprazolam    O
,    O
bromazepam    O
,    O
brotizolam    O
,    O
flunitrazepam    B-Sedative104166553
,    O
loprazolam    B-Sedative104166553
,    O
lorazepam    O
,    O
lormetazepam    B-Sedative104166553
,    O
midazolam    O
,    O
nitrazepam    O
,    O
oxazepam    O
,    O
and    O
temazepam    O
.    O

On    O
July    O
24th    O
,    O
1996    O
,    O
Ray    O
's    O
daughter    O
,    O
who    O
was    O
friends    O
with    O
Garrett    O
,    O
took    O
her    O
to    O
the    O
Blu    O
-    O
Water    O
Saloon    O
in    O
T    O
Or    O
C    O
,    O
and    O
roofied    B-Sedative104166553
the    O
beer    O
she    O
was    O
drinking    O
.    O

Mitch    O
retaliates    O
by    O
forcing    O
Adam    O
to    O
admit    O
that    O
he    O
gave    O
a    O
fellow    O
classmate    O
roofies    B-Sedative104166553
at    O
a    O
party    O
,    O
date    O
-    O
raped    O
her    O
when    O
she    O
was    O
unconscious    O
and    O
then    O
forced    O
her    O
to    O
get    O
an    O
abortion    O
when    O
he    O
discovered    O
that    O
she    O
was    O
pregnant    O
.    O

One    O
of    O
Tracy    O
's    O
biggest    O
legislative    O
accomplishments    O
was    O
his    O
placing    O
the    O
Hoffman    O
-    O
LaRoche    O
drug    O
Rohypnol    O
-    O
known    O
clinically    O
as    O
flunitrazepam    B-Sedative104166553
and    O
commonly    O
as    O
"    O
roofies    O
"    O
-    O
in    O
Schedule    O
I    O
of    O
the    O
state    O
statutes    O
,    O
effectively    O
banning    O
the    O
date    B-Sedative104166553
rape    I-Sedative104166553
drug    I-Sedative104166553
in    O
Florida    O
with    O
severe    O
penalties    O
for    O
its    O
possession    O
and    O
use    O
.    O

This    O
disorder    O
is    O
usually    O
acquired    O
in    O
one    O
of    O
four    O
ways    O
:    O
One    O
cause    O
is    O
benzodiazepine    O
drugs    O
such    O
as    O
;    O
midazolam    O
,    O
flunitrazepam    B-Sedative104166553
,    O
lorazepam    O
,    O
temazepam    O
,    O
nitrazepam    O
,    O
triazolam    O
,    O
clonazepam    B-Sedative104166553
,    O
alprazolam    O
,    O
diazepam    O
,    O
and    O
nimetazepam    O
;    O
all    O
of    O
which    O
are    O
known    O
to    O
have    O
powerful    O
amnesic    O
effects    O
.    O

Benzodiazepines    O
more    O
likely    O
to    O
cause    O
euphoria    O
are    O
flunitrazepam    B-Sedative104166553
,    O
alprazolam    O
and    O
clonazepam    B-Sedative104166553
.    O

Meanwhile    O
,    O
Madison    O
is    O
tricked    O
by    O
Kyle    O
's    O
frat    O
brother    O
Archie    O
Brener    O
(    O
Grey    O
Damon    O
)    O
into    O
using    O
a    O
spiked    B-Sedative104166553
matchstick    O
for    O
her    O
cigarette    O
,    O
and    O
he    O
subsequently    O
drags    O
her    O
into    O
a    O
room    O
with    O
the    O
other    O
frat    O
brothers    O
and    O
they    O
gang    O
-    O
rape    O
her    O
.    O

A    O
few    O
days    O
later    O
,    O
Michelle    O
does    O
a    O
drug    O
test    O
and    O
is    O
told    O
that    O
Rohypnol    B-Sedative104166553
was    O
used    O
to    O
abduct    O
her    O
.    O

Additionally    O
,    O
IV    O
sedation    O
is    O
frequently    O
administered    O
as    O
a    O
concoction    O
of    O
several    O
agents    O
including    O
those    O
previously    O
mentioned    O
for    O
induction    O
and    O
maintenance    O
of    O
anesthesia    O
,    O
as    O
well    O
as    O
a    O
benzodiazepine    O
(    O
usually    O
midazolam    O
,    O
but    O
temazepam    O
or    O
flunitrazepam    B-Sedative104166553
are    O
also    O
used    O
via    O
the    O
oral    O
route    O
)    O
and    O
a    O
narcotic    O
/    O
systemic    O
analgesic    O
such    O
as    O
demerol    O
or    O
fentanyl    O
.    O

Oxanamide    B-Sedative104166553
(    O
Quiactin    B-Sedative104166553
)    O
is    O
an    O
anxiolytic    O
and    O
muscle    O
relaxant    O
which    O
can    O
produce    O
sedative    O
and    O
hypnotic    O
effects    O
in    O
sufficiently    O
high    O
doses    O
.    O

L-733,060    B-Sedative104166553

Pazinaclone    O
(    O
DN-2327    O
)    O
is    O
a    O
sedative    O
and    O
anxiolytic    O
drug    O
in    O
the    O
cyclopyrrolone    B-Sedative104166553
family    O
of    O
drugs    O
.    O

Suproclone    O
is    O
a    O
sedative    O
and    O
anxiolytic    O
drug    O
in    O
the    O
cyclopyrrolone    B-Sedative104166553
family    O
of    O
drugs    O
,    O
developed    O
by    O
the    O
French    O
pharmaceutical    O
company    O
RhÃ´ne    O
-    O
Poulenc    O
.    O

:    O
N05CM13    O
Valnoctamide    B-Sedative104166553

Butabarbital    O
can    O
be    O
hydrolyzed    O
to    O
Valnoctamide    B-Sedative104166553
.    O

Olanzapine    B-Sedative104166553

Few    O
available    O
atypical    O
antipsychotics    O
are    O
known    O
to    O
possess    O
antidepressant    O
efficacy    O
in    O
bipolar    O
disorder    O
(    O
with    O
the    O
notable    O
exceptions    O
being    O
quetiapine    O
,    O
olanzapine    B-Sedative104166553
and    O
possibly    O
asenapine    B-Sedative104166553
)    O
as    O
a    O
monotherapy    O
,    O
even    O
though    O
the    O
majority    O
of    O
atypical    O
antipsychotics    O
are    O
known    O
to    O
possess    O
significant    O
antimanic    O
activity    O
,    O
which    O
is    O
yet    O
to    O
be    O
clearly    O
demonstrated    O
for    O
lurasidone    O
.    O

In    O
animal    O
studies    O
,    O
it    O
reversed    O
dizocilpine    O
-    O
induced    O
learning    O
and    O
memory    O
impairment    O
and    O
was    O
found    O
to    O
be    O
superior    O
in    O
doing    O
this    O
to    O
all    O
of    O
the    O
other    O
antipsychotics    O
examined    O
,    O
including    O
risperidone    O
,    O
olanzapine    B-Sedative104166553
,    O
quetiapine    O
,    O
clozapine    O
,    O
aripiprazole    B-Sedative104166553
,    O
and    O
haloperidol    O
.    O

Olanzapine    B-Sedative104166553

Olanzapine    B-Sedative104166553

Olanzapine    B-Sedative104166553

Olanzapine    B-Sedative104166553

Olanzapine    B-Sedative104166553

Its    O
use    O
in    O
intramuscular    O
sedation    O
has    O
been    O
replaced    O
by    O
intramuscular    O
preparations    O
of    O
haloperidol    O
,    O
midazolam    O
,    O
clonazepam    B-Sedative104166553
and    O
olanzapine    B-Sedative104166553
.    O

Olanzapine    B-Sedative104166553
(    O
Zyprexa    O
)    O

Olanzapine    B-Sedative104166553
,    O
atypical    O
antipsychotic    O
and    O
mood    O
stabilizer    O

Olanzapine    B-Sedative104166553
may    O
be    O
an    O
effective    O
monotherapy    O
in    O
psychotic    O
depression    O
,    O
although    O
there    O
is    O
evidence    O
that    O
it    O
is    O
ineffective    O
for    O
depressive    O
symptoms    O
as    O
a    O
monotherapy    O
;    O
and    O
olanzapine    O
/    O
fluoxetine    O
is    O
more    O
effective    O
.    O

Olanzapine    B-Sedative104166553
/    O
sertraline    O

Some    O
antipsychotic    O
agents    O
may    O
be    O
more    O
risky    O
during    O
withdrawal    O
than    O
others    O
,    O
especially    O
clozapine    O
,    O
olanzapine    B-Sedative104166553
or    O
low    O
potency    O
phenothiazines    O
(    O
e.g.    O
,    O
chlorpromazine    O
)    O
,    O
as    O
they    O
lower    O
the    O
seizure    O
threshold    O
and    O
can    O
worsen    O
withdrawal    O
effects    O
;    O
if    O
used    O
,    O
extreme    O
caution    O
is    O
required    O
.    O

This    O
is    O
a    O
list    O
of    O
adverse    O
effects    O
of    O
the    O
antipsychotic    O
olanzapine    B-Sedative104166553
,    O
sorted    O
by    O
frequency    O
of    O
occurrence    O
.    O

Review    O
of    O
treatment    O
of    O
excoriation    O
disorder    O
have    O
shown    O
that    O
the    O
following    O
medications    O
may    O
be    O
effective    O
in    O
reducing    O
picking    O
behavior    O
:    O
doxepin    O
,    O
clomipramine    O
,    O
naltrexone    O
,    O
pimozide    O
,    O
and    O
olanzapine    B-Sedative104166553
.    O

In    O
one    O
case    O
,    O
a    O
patient    O
had    O
not    O
been    O
responding    O
to    O
haloperidol    O
,    O
thus    O
the    O
physician    O
tried    O
olanzapine    B-Sedative104166553
.    O

Olanzapine    B-Sedative104166553

Quetiapine    O
,    O
sulpiride    B-Sedative104166553
and    O
olanzapine    B-Sedative104166553
,    O
the    O
atypical    O
neuroleptic    O
agents    O
,    O
are    O
less    O
likely    O
to    O
yield    O
drug    O
-    O
induced    O
parkinsonism    O
and    O
tardive    O
dyskinesia    O

Olanzapine    B-Sedative104166553

Clocapramine    B-Sedative104166553
(    O
Clofekton    B-Sedative104166553
,    O
Padrasen    B-Sedative104166553
)    O
,    O
also    O
known    O
as    O
3-chlorocarpipramine    B-Sedative104166553
,    O
is    O
an    O
atypical    B-Sedative104166553
antipsychotic    I-Sedative104166553
of    O
the    O
imidobenzyl    O
class    O
which    O
was    O
introduced    O
in    O
Japan    O
in    O
1974    O
by    O
Yoshitomi    O
for    O
the    O
treatment    O
of    O
schizophrenia    O
.    O

Gidazepam    B-Sedative104166553

Panadiplon    B-Sedative104166553
(    O
U-78875    B-Sedative104166553
)    O
is    O
an    O
anxiolytic    O
drug    O
with    O
a    O
novel    O
chemical    O
structure    O
that    O
is    O
not    O
closely    O
related    O
to    O
other    O
drugs    O
of    O
this    O
type    O
.    O

Triflunordazepam    B-Sedative104166553
(    O
also    O
known    O
as    O
Ro5-2904    B-Sedative104166553
)    O
is    O
a    O
drug    O
which    O
is    O
a    O
benzodiazepine    O
derivative    O
with    O
high    O
GABAA    O
receptor    O
affinity    O
,    O
and    O
has    O
anticonvulsant    O
effects    O
.    O

:    O
N05BA07    O
Adinazolam    B-Sedative104166553

Adinazolam    B-Sedative104166553

Benzquinamide    B-Sedative104166553
is    O
a    O
discontinued    O
antiemetic    O
drug    O
used    O
in    O
post    O
-    O
operative    O
care    O
.    O

Ripazepam    O
is    O
a    O
pyrazolodiazepinone    O
derivative    O
structurally    O
related    O
to    O
certain    O
benzodiazepine    O
drugs    O
,    O
especially    O
zolazepam    B-Sedative104166553
.    O

Saredutant    B-Sedative104166553
(    O
SR-48,968    B-Sedative104166553
)    O
is    O
a    O
drug    O
that    O
acts    O
as    O
a    O
NK2    O
receptor    O
antagonist    O
.    O

Vabicaserin    B-Sedative104166553

ATC-0175    B-Sedative104166553

DAA-1106    B-Sedative104166553

Selank    B-Sedative104166553

Fluperlapine    B-Sedative104166553

Mecloqualone    B-Sedative104166553

Mecloqualone    B-Sedative104166553

Benzobarbital    B-Sedative104166553
(    O
Benzonal    O
)    O
is    O
a    O
barbiturate    O
derivative    O
.    O

Lactation    O
failure    O
can    O
be    O
treated    O
with    O
a    O
galactagogue    O
(    O
lactation    O
-    O
promoting    O
agent    O
)    O
such    O
as    O
a    O
D2    O
receptor    O
antagonist    O
like    O
domperidone    O
,    O
metoclopramide    O
,    O
or    O
certain    O
antipsychotics    O
like    O
chlorpromazine    O
,    O
haloperidol    O
,    O
sulpiride    B-Sedative104166553
,    O
or    O
risperidone    O
,    O
an    O
oxytocic    O
such    O
as    O
oxytocin    O
or    O
an    O
analogue    O
like    O
carbetocin    O
or    O
demoxytocin    O
,    O
with    O
GH    O
(    O
or    O
potentially    O
with    O
a    O
growth    O
hormone    O
secretagogue    O
,    O
alternatively    O
)    O
,    O
or    O
with    O
thyrotropin    O
-    O
releasing    O
hormone    O
(    O
TRH    O
)    O
or    O
thyroid    O
-    O
stimulating    O
hormone    O
(    O
TSH    O
)    O
.    O

That    O
research    O
project    O
also    O
produced    O
the    O
product    O
sulpiride    B-Sedative104166553
.    O

The    O
D2    O
receptor    O
is    O
involved    O
in    O
the    O
regulation    O
of    O
prolactin    O
secretion    O
,    O
and    O
agonists    O
of    O
the    O
receptor    O
such    O
as    O
bromocriptine    O
and    O
cabergoline    O
decrease    O
prolactin    O
levels    O
while    O
antagonists    O
of    O
the    O
receptor    O
such    O
as    O
domperidone    O
,    O
metoclopramide    O
,    O
haloperidol    O
,    O
risperidone    O
,    O
and    O
sulpiride    B-Sedative104166553
increase    O
prolactin    O
levels    O
.    O

Quetiapine    O
,    O
sulpiride    B-Sedative104166553
and    O
olanzapine    B-Sedative104166553
,    O
the    O
atypical    O
neuroleptic    O
agents    O
,    O
are    O
less    O
likely    O
to    O
yield    O
drug    O
-    O
induced    O
parkinsonism    O
and    O
tardive    O
dyskinesia    O

Taniplon    B-Sedative104166553
is    O
a    O
nonbenzodiazepine    B-Sedative104166553
anxiolytic    O
drug    O
from    O
the    O
imidazoquinazoline    O
family    O
of    O
drugs    O
.    O

At    O
about    O
200    O
Â°C    O
in    O
the    O
presence    O
of    O
soluble    O
ruthenium    O
catalysts    O
,    O
the    O
diol    O
undergoes    O
dehydrogenation    O
to    O
form    O
butyrolactone    B-Sedative104166553
.    O

In    O
the    O
United    O
Kingdom    O
,    O
1,4-butanediol    O
was    O
scheduled    O
in    O
December    O
2009    O
(    O
along    O
with    O
another    O
GHB    O
precursor    O
,    O
gamma-butyrolactone    B-Sedative104166553
)    O
as    O
a    O
Class    O
C    O
controlled    O
substance    O
.    O

Metabolic    O
pathway    O
of    O
1,4-butanediol    O
,    O
Î³-butyrolactone    B-Sedative104166553
and    O
Î³-hydroxybutyric    B-Sedative104166553
acid    I-Sedative104166553
(GHB)    I-Sedative104166553
.    O

The    O
young    O
men    O
brought    O
them    O
the    O
cocktails    O
,    O
to    O
which    O
they    O
had    O
added    O
either    O
gamma-hydroxybutyric    B-Sedative104166553
acid    I-Sedative104166553
(    O
GHB    O
)    O
or    O
gamma-butyrolactone    B-Sedative104166553
(    O
GBL    O
)    O
.    O

(    O
B    O
)    O
The    O
designation    O
of    O
gamma    B-Sedative104166553
butyrolactone    I-Sedative104166553
or    O
any    O
other    O
chemical    O
as    O
a    O
listed    O
chemical    O
pursuant    O
to    O
paragraph    O
(    O
34    O
)    O
or    O
(    O
35    O
)    O
does    O
not    O
preclude    O
a    O
finding    O
pursuant    O
to    O
subparagraph    O
(    O
A    O
)    O
of    O
this    O
paragraph    O
that    O
the    O
chemical    O
is    O
a    O
controlled    O
substance    O
analogue    O
.    O

GBL    B-Sedative104166553

Î³-Butyrolactone    B-Sedative104166553

In    O
November    O
2005    O
,    O
Rose    O
was    O
indicted    O
for    O
distributing    O
gamma-Butyrolactone    B-Sedative104166553
(    O
GBL    O
)    O
to    O
his    O
Lookouts    O
teammates    O
in    O
the    O
late    O
1990s    O
.    O

Benzodiazepines    O
developed    O
more    O
recently    O
(    O
e.g.    O
remimazolam    B-Sedative104166553
,    O
QH-ii-066    B-Sedative104166553
,    O
Ro48-6791    B-Sedative104166553
etc    O
.    O
)    O

Blue    B-Sedative104166553
88    I-Sedative104166553
was    O
a    O
blue    O
-    O
colored    O
pill    O
that    O
was    O
a    O
mix    O
of    O
calming    O
drugs    O
,    O
mainly    O
barbiturates    O
such    O
as    O
sodium    O
amytal    O
,    O
used    O
to    O
treat    O
American    O
soldiers    O
in    O
the    O
Second    O
World    O
War    O
who    O
suffered    O
from    O
battle    O
fatigue    O
.    O

oxazolam    B-Sedative104166553

CL-218,872    B-Sedative104166553

doxefazepam    B-Sedative104166553
(    O
INN    O
)    O

Reclazepam    B-Sedative104166553
is    O
a    O
drug    O
which    O
is    O
a    O
benzodiazepine    O
derivative    O
.    O

As    O
effective    O
as    O
iloperidone    O
,    O
and    O
13    O
to    O
15%    O
less    O
effective    O
than    O
ziprasidone    B-Sedative104166553
,    O
chlorpromazine    O
,    O
and    O
asenapine    B-Sedative104166553
.    O

Lurasidone    O
shows    O
a    O
very    O
close    O
pharmacological    O
profile    O
and    O
has    O
been    O
synthesized    O
similarly    O
to    O
Ziprasidone    B-Sedative104166553
.    O

Ziprasidone    B-Sedative104166553
(    O
Partial    O
agonist    O
,    O
Ki    O
=    O
3.4    O
nM    O
)    O

Ziprasidone    B-Sedative104166553

Ziprasidone    B-Sedative104166553

Ziprasidone    B-Sedative104166553

Ziprasidone    B-Sedative104166553
(    O
Geodon    O
)    O

Some    O
anti    O
-    O
psychotic    O
drugs    O
,    O
such    O
as    O
haloperidol    O
and    O
ziprasidone    B-Sedative104166553
,    O
have    O
a    O
prolonged    O
QT    O
interval    O
as    O
a    O
rare    O
side    O
-    O
effect    O
.    O

Ziprasidone    B-Sedative104166553

Ziprasidone    B-Sedative104166553

Etifoxine    B-Sedative104166553

;    O
First-generation    B-Sedative104166553

Fluspirilene    O
(    O
Redeptin    O
,    O
Imap    O
,    O
R6218    O
)    O
is    O
a    O
diphenylbutylpiperidine    O
typical    B-Sedative104166553
antipsychotic    I-Sedative104166553
drug    O
,    O
used    O
for    O
the    O
treatment    O
of    O
schizophrenia    O
.    O

Typical    B-Sedative104166553
antipsychotic    I-Sedative104166553

Typical    B-Sedative104166553
antipsychotic    I-Sedative104166553

Patients    O
with    O
intense    O
intrusive    O
thoughts    O
that    O
do    O
not    O
respond    O
to    O
SSRIs    O
or    O
other    O
antidepressants    O
may    O
be    O
prescribed    O
typical    B-Sedative104166553
and    O
atypical    B-Sedative104166553
neuroleptics    O
including    O
risperidone    O
(    O
trade    O
name    O
Risperdal    O
)    O
,    O
ziprasidone    B-Sedative104166553
(    O
Geodon    O
)    O
,    O
haloperidol    O
(    O
Haldol    O
)    O
,    O
and    O
pimozide    O
(    O
Orap    O
)    O
.    O

Typical    B-Sedative104166553

Since    O
his    O
committal    O
Hunt    O
has    O
been    O
forcibly    O
medicated    O
with    O
a    O
diverse    O
range    O
of    O
psychoactive    O
drugs    O
including    O
the    O
typical    B-Sedative104166553
antipsychotic    I-Sedative104166553
zuclopenthixol    O
and    O
chlorpromazine    O
,    O
the    O
atypical    B-Sedative104166553
antipsychotic    I-Sedative104166553
amisulpride    O
,    O
benzodiazepines    O
and    O
sleeping    O
tablets    O
.    O

Typical    B-Sedative104166553
and    O
atypical    B-Sedative104166553
antipsychotics    I-Sedative104166553
have    O
been    O
shown    O
to    O
be    O
helpful    O
in    O
the    O
early    O
stages    O
of    O
treatment    O
.    O

The    O
typical    B-Sedative104166553
antipsychotics    I-Sedative104166553
,    O
such    O
as    O
chlorpromazine    O
and    O
haloperidol    O
,    O
are    O
potent    O
D2    O
receptor    O
antagonists    O
.    O

being    O
switched    O
to    O
another    O
atypical    O
antipsychotic    O
,    O
the    O
addition    O
of    O
a    O
mood    O
stabilizer    O
such    O
as    O
lithium    O
or    O
an    O
anticonvulsant    O
,    O
or    O
being    O
switched    O
to    O
a    O
typical    B-Sedative104166553
antipsychotic    I-Sedative104166553
.    O

Typical    B-Sedative104166553
antipsychotics    I-Sedative104166553

There    O
are    O
two    O
categories    O
of    O
antipsychotics    O
:    O
typical    B-Sedative104166553
antipsychotic    I-Sedative104166553
and    O
atypical    B-Sedative104166553
antipsychotic    I-Sedative104166553
.    O

It    O
tends    O
to    O
produce    O
hyperolactinaemia    O
less    O
often    O
than    O
risperidone    O
,    O
paliperidone    O
and    O
the    O
typical    B-Sedative104166553
antipsychotics    I-Sedative104166553
but    O
more    O
often    O
than    O
quetiapine    O
and    O
clozapine    O
.    O

Amitriptyline/perphenazine    B-Sedative104166553
(    O
Duo-Vil    B-Sedative104166553
,    O
Etrafon    B-Sedative104166553
,    O
Triavil    B-Sedative104166553
,    O
Triptafen    B-Sedative104166553
)    O
is    O
a    O
formulation    O
that    O
contains    O
the    O
tricyclic    O
antidepressant    O
amitriptyline    O
and    O
the    O
medium    O
-    O
potency    O
typical    B-Sedative104166553
(first-generation)    I-Sedative104166553
antipsychotic    I-Sedative104166553
,    O
perphenazine    O
.    O

Chloral    B-Sedative104166553
betaine    I-Sedative104166553

Fletazepam    B-Sedative104166553
is    O
a    O
drug    O
which    O
is    O
a    O
benzodiazepine    O
derivative    O
.    O

DAA-1097    B-Sedative104166553

lirequinil    B-Sedative104166553
(    O
INN    O
)    O

lenperone    B-Sedative104166553
(    O
INN    O
)    O

Bucolome    B-Sedative104166553
(    O
Paramidine    B-Sedative104166553
)    O
is    O
a    O
barbiturate    O
derivative    O
.    O

Triflubazam    B-Sedative104166553

Dacrycarpus    O
imbricatus    O
-    O
Daewoo    O
Precision    O
Industries    O
K2    O
-    O
Daily    O
Post    O
(    O
Fiji    O
)    O
-    O
Keni    O
DAKUIDREKETI    O
-    O
Joe    O
DAKUITOGA    O
-    O
Dakuwaqa    O
-    O
Dama    O
River    O
-    O
Dance    O
in    O
Rotuma    O
-    O
Danube    O
(    O
ship    O
)    O
-    O
Quazi    O
Golam    O
DASTGIR    O
-    O
Daucina    O
-    O
Jone    O
DAUNIVUCU    O
-    O
Waisea    O
DAVETA    O
-    O
Samuela    O
DAVETAWALU    O
-    O
Vilimaina    O
DAVU    O
-    O
Davuilevu    O
-    O
Dawacumu    O
River    O
-    O
Dawasamu    O
River    O
-    O
Daylight    O
saving    O
time    O
in    O
Fiji    O
-    O
Noor    O
DEAN    O
-    O
Deans    O
Trophy    O
-    O
Degei    O
-    O
Apisalome    O
DEGEI    O
-    O
Degeneriaceae    O
-    O
Jone    O
DELAI    O
-    O
DELAILOA    O
-    O
Nelson    O
DELAILOMALOMA    O
-    O
Iliesa    O
DELANA    O
-    O
Vilimoni    O
DELASAU    O
-    O
Demographics    O
of    O
Fiji    O
-    O
Denarau    O
Island    O
-    O
Roshika    O
DEO    O
-    O
Vishnu    O
DEO    O
-    O
Andrew    O
DEOKI    O
-    O
Ram    O
Narayan    O
DEOKI    O
-    O
Deorbit    O
of    O
Mir    O
-    O
Derek    O
DERENALAGI    O
-    O
James    O
Herman    O
DE    O
RICCI    O
-    O
Desmethoxyyangonin    O
-    O
Sir    O
William    O
DES    O
VÅUX    O
-    O
Deuba    O
River    O
-    O
DEUCE    O
-    O
Graham    O
DEWES    O
-    O
Dhantal    O
-    O
Digicel    O
Cup    O
-    O
Laisa    O
DIGITAKI    O
-    O
Dihydrokavain    B-Sedative104166553
-    O
Dihydromethysticin    B-Sedative104166553
-    O
Ratu    O
Josefa    O
DIMURI    O
-    O
Larry    O
Miles    O
DINGER    O
-    O
Diospyros    O
fasciculosa    O
-    O
Diplomatic    O
missions    O
in    O
Fiji    O
,    O
list    O
of    O
-    O
Diplomatic    O
missions    O
of    O
Fiji    O
,    O
list    O
of    O
-    O
Diplomatic    O
relations    O
of    O
Fiji    O
-    O
Director    O
of    O
Public    O
Prosecutions    O
(    O
Fiji    O
)    O
-    O
Iowane    O
DIVAVESI    O
-    O
Manoa    O
DOBUI    O
-    O
Manilal    O
DOCTOR    O
-    O
Dodonu    O
ni    O
Taukei    O
-    O
Keni    O
DOIDOI    O
-    O
Vyacheslav    O
DOLGOV    O
-    O
Dominion    O
of    O
Fiji    O
-    O
Isoa    O
DOMOLAILAI    O
-    O
Sam    O
DOMONI    O
-    O
William    O
Earnest    O
DONNELLY    O
-    O
Alifereti    O
DOVIVERATA    O
-    O
Brian    O
Andre    O
DOYLE    O
-    O
Drakaniwai    O
River    O
-    O
Dranivia    O
-    O
Misaele    O
DRAUNIBAKA    O
-    O
Savenaca    O
DRAUNIDALO    O
-    O
Tupou    O
DRAUNIDALO    O
-    O
Dravuni    O
-    O
Drawa    O
River    O
-    O
Dreketi    O
F.C.    O
-    O
Dreketi    O
River    O
-    O
Pita    O
DRITI    O
-    O
Asaeli    O
DRIU    O
-    O
Moses    O
DRIVER    O
-    O
Ema    O
DRUAVESI    O
-    O
Hannah    O
DUDLEY    O
-    O
Dudley    O
High    O
School    O
-    O
Alfred    O
DUFTY    O
-    O
Colin    O
DUFTY    O
-    O
Francis    O
Herbert    O
DUFTY    O
-    O
Adi    O
Litia    O
Mara    O
DUGDALE    O
-    O
Maciu    O
DUNADAMU    O
-    O
Shanti    O
DUT    O
-    O
Yogendra    O
DUTT    O
-    O
Iliesa    O
DUVULOCO    O
-    O
Lagi    O
DYER    O
-    O
Adi    O
Senimili    O
DYER    O

#    O
Delorazepam    B-Sedative104166553

delorazepam    B-Sedative104166553

Mebroqualone    B-Sedative104166553

#    O
Camazepam    B-Sedative104166553

camazepam    B-Sedative104166553

emylcamate    B-Sedative104166553
(    O
INN    O
)    O

Cloroqualone    B-Sedative104166553

Aripiprazole    B-Sedative104166553

In    O
a    O
2013    O
meta    O
-    O
analysis    O
of    O
the    O
efficacy    O
and    O
tolerability    O
of    O
15    O
antipsychotic    O
drugs    O
it    O
was    O
found    O
to    O
produce    O
the    O
second    O
least    O
(    O
after    O
haloperidol    O
)    O
weight    O
gain    O
,    O
the    O
least    O
QT    O
interval    O
prolongation    O
,    O
the    O
fourth    O
"    O
most    O
"    O
extrapyramidal    O
side    O
effects    O
(    O
after    O
haloperidol    O
,    O
zotepine    O
and    O
chlorpromazine    O
)    O
and    O
the    O
sixth    O
least    O
sedation    O
(    O
after    O
paliperidone    O
,    O
sertindole    B-Sedative104166553
,    O
amisulpride    O
,    O
iloperidone    O
and    O
aripiprazole    B-Sedative104166553
)    O
.    O

In    O
animal    O
studies    O
,    O
it    O
reversed    O
dizocilpine    O
-    O
induced    O
learning    O
and    O
memory    O
impairment    O
and    O
was    O
found    O
to    O
be    O
superior    O
in    O
doing    O
this    O
to    O
all    O
of    O
the    O
other    O
antipsychotics    O
examined    O
,    O
including    O
risperidone    O
,    O
olanzapine    B-Sedative104166553
,    O
quetiapine    O
,    O
clozapine    O
,    O
aripiprazole    B-Sedative104166553
,    O
and    O
haloperidol    O
.    O

Aripiprazole    B-Sedative104166553
(    O
atypical    O
antipsychotic    O
)    O

Aripiprazole    B-Sedative104166553

Aripiprazole    B-Sedative104166553

Aripiprazole    B-Sedative104166553

Aripiprazole    B-Sedative104166553
(    O
weak    O
partial    O
agonist    O
)    O

Aripiprazole    B-Sedative104166553

Aripiprazole    B-Sedative104166553
(    O
Abilify    O
)    O

Tends    O
to    O
produce    O
a    O
moderate    O
amount    O
of    O
sedation    O
,    O
less    O
than    O
clozapine    O
and    O
chlorpromazine    O
but    O
more    O
than    O
aripiprazole    B-Sedative104166553
,    O
amisulpride    O
,    O
paliperidone    O
and    O
sertindole    B-Sedative104166553
and    O
approximately    O
that    O
of    O
quetiapine    O
and    O
risperidone    O
.    O

He    O
was    O
among    O
the    O
first    O
to    O
demonstrate    O
co    O
-    O
transmission    O
in    O
the    O
1970s    O
and    O
also    O
played    O
a    O
pivotal    O
role    O
in    O
developing    O
the    O
atypical    B-Sedative104166553
antipsychotic    I-Sedative104166553
,    O
aripiprazole    B-Sedative104166553
.    O

Aripiprazole    B-Sedative104166553
(    O
weak    O
partial    O
agonist    O
)    O

Desbutal    B-Sedative104166553

Nitromethaqualone    B-Sedative104166553

Bentazepam    B-Sedative104166553
(    O
also    O
known    O
as    O
Thiadipone    B-Sedative104166553
,    O
Tiadipona    B-Sedative104166553
)    O
is    O
a    O
thienodiazepine    O
which    O
is    O
a    O
benzodiazepine    O
analog    O
.    O

Bromoureides    B-Sedative104166553
are    O
sedative    O
-    O
hypnotics    O
available    O
mainly    O
in    O
Europe    O
,    O
including    O
acecarbromal    O
,    O
bromisoval    O
,    O
and    O
carbromal    O
(    O
Horowitz    O
,    O
1997    O
)    O
.    O

Metopimazine    B-Sedative104166553
(    O
INN    O
)    O

Ipsapirone    B-Sedative104166553
-    O
anxiolytic    O

Flubromazolam    B-Sedative104166553

Many    O
atypical    B-Sedative104166553
antipsychotic    I-Sedative104166553
and    O
azapirones    O
like    O
buspirone    O
and    O
gepirone    B-Sedative104166553
(    O
via    O
metabolite    O
pyrimidinylpiperazine    O
)    O
antagonize    O
Î±2-adrenergic    O
receptors    O
as    O
well    O
.    O

Atypical    B-Sedative104166553
antipsychotic    I-Sedative104166553
are    O
modestly    O
useful    O
in    O
reducing    O
aggression    O
and    O
psychosis    O
in    O
people    O
with    O
Alzheimer    O
's    O
disease    O
,    O
but    O
their    O
advantages    O
are    O
offset    O
by    O
serious    O
adverse    O
effects    O
,    O
such    O
as    O
stroke    O
,    O
movement    O
difficulties    O
or    O
cognitive    O
decline    O
.    O

Lurasidone    B-Sedative104166553
(    O
trade    O
name    O
Latuda    B-Sedative104166553
)    O
is    O
an    O
atypical    B-Sedative104166553
antipsychotic    I-Sedative104166553
developed    O
by    O
Dainippon    O
Sumitomo    O
Pharma    O
and    O
marketed    O
by    O
Sunovion    O
in    O
the    O
U.S.    O

Atypical    B-Sedative104166553
antipsychotic    I-Sedative104166553

Atypical    B-Sedative104166553
antipsychotic    I-Sedative104166553
(    O
antagonist    O
)    O

Dexmedetomidine    B-Sedative104166553
and    O
atypical    B-Sedative104166553
antipsychotic    I-Sedative104166553
agents    I-Sedative104166553
are    O
other    O
premedications    O
which    O
are    O
used    O
particularly    O
in    O
very    O
uncooperative    O
children    O
.    O

Like    O
schizophrenia    O
,    O
schizophreniform    O
disorder    O
is    O
often    O
treated    O
with    O
antipsychotic    O
medications    O
,    O
especially    O
the    O
atypicals    B-Sedative104166553
,    O
along    O
with    O
a    O
variety    O
of    O
social    O
supports    O
(    O
such    O
as    O
individual    O
psychotherapy    O
,    O
family    O
therapy    O
,    O
occupational    O
therapy    O
,    O
etc    O
.    O
)    O

The    O
medications    O
used    O
are    O
largely    O
the    O
same    O
as    O
those    O
used    O
to    O
treat    O
schizophrenia    O
,    O
with    O
an    O
atypical    B-Sedative104166553
antipsychotic    I-Sedative104166553
as    O
the    O
usual    O
drug    O
of    O
choice    O
.    O

Atypical    B-Sedative104166553
antipsychotics    I-Sedative104166553
(    O
except    O
aripiprazole    O
,    O
brexpiprazole    O
,    O
and    O
any    O
other    O
D2    O
receptor    O
partial    O
agonists    O
)    O

Atypical    B-Sedative104166553
antipsychotic    I-Sedative104166553
are    O
also    O
used    O
as    O
mood    O
stabilizers    O
in    O
the    O
treatment    O
of    O
bipolar    O
disorder    O
,    O
and    O
they    O
can    O
augment    O
the    O
action    O
of    O
antidepressants    O
in    O
major    O
depressive    O
disorder    O
.    O

There    O
are    O
two    O
categories    O
of    O
antipsychotics    O
:    O
typical    B-Sedative104166553
antipsychotic    I-Sedative104166553
and    O
atypical    B-Sedative104166553
antipsychotic    I-Sedative104166553
.    O

Besides    O
lithium    O
,    O
several    O
anticonvulsants    O
and    O
atypical    B-Sedative104166553
antipsychotic    I-Sedative104166553
have    O
mood    O
stabilizing    O
activity    O
.    O

Addition    O
of    O
atypical    B-Sedative104166553
antipsychotic    I-Sedative104166553
when    O
the    O
patient    O
has    O
not    O
responded    O
to    O
an    O
antidepressant    O
is    O
also    O
known    O
to    O
increase    O
the    O
effectiveness    O
of    O
antidepressant    O
drugs    O
,    O
albeit    O
at    O
the    O
cost    O
of    O
more    O
frequent    O
and    O
potentially    O
serious    O
side    O
effects    O
.    O

Pharmaceutical    O
treatments    O
can    O
include    O
tricyclic    O
antidepressants    O
,    O
atypical    B-Sedative104166553
antipsychotics    I-Sedative104166553
,    O
or    O
a    O
combination    O
of    O
an    O
antidepressant    O
from    O
the    O
newer    O
,    O
more    O
well    O
tolerated    O
SSRI    O
or    O
SNRI    O
categories    O
and    O
an    O
atypical    O
antipsychotic    O
.    O

Atypical    B-Sedative104166553
antipsychotic    I-Sedative104166553
medications    O
may    O
also    O
be    O
used    O
for    O
bipolar    O
disorder    O
,    O
often    O
in    O
combination    O
with    O
antidepressant    O
medications    O
.    O

Antipsychotics    O
and    O
atypical    B-Sedative104166553
antipsychotic    I-Sedative104166553
are    O
the    O
major    O
classes    O
of    O
medications    O
used    O
to    O
treat    O
schizophrenia    O
.    O

Cariprazine    B-Sedative104166553
,    O
sold    O
under    O
the    O
brand    O
names    O
Vraylar    B-Sedative104166553
in    O
the    O
United    O
States    O
and    O
Reagila    B-Sedative104166553
in    O
Europe    O
,    O
is    O
an    O
atypical    B-Sedative104166553
antipsychotic    I-Sedative104166553
which    O
is    O
used    O
in    O
the    O
treatment    O
of    O
schizophrenia    O
and    O
bipolar    O
mania    O
.    O

A    O
potential    O
explanation    O
as    O
to    O
why    O
levofenfluramine    O
is    O
not    O
similarly    O
an    O
effective    O
anorectic    O
is    O
that    O
it    O
has    O
also    O
been    O
found    O
to    O
behave    O
as    O
a    O
dopamine    O
receptor    O
antagonist    O
,    O
which    O
,    O
as    O
dopamine    O
antagonists    O
like    O
atypical    B-Sedative104166553
antipsychotic    I-Sedative104166553
are    O
associated    O
with    O
causing    O
increased    O
appetite    O
and    O
weight    O
gain    O
â    O
effects    O
that    O
their    O
actions    O
on    O
dopamine    O
receptors    O
have    O
been    O
implicated    O
in    O
playing    O
a    O
role    O
in    O
the    O
development    O
of    O
,    O
is    O
an    O
action    O
that    O
could    O
in    O
theory    O
cancel    O
out    O
the    O
hypothetical    O
serotonergically    O
-    O
mediated    O
appetite    O
suppressant    O
effects    O
of    O
the    O
compound    O
.    O

According    O
to    O
Nash    O
,    O
the    O
film    O
"    O
A    O
Beautiful    O
Mind    O
"    O
inaccurately    O
implied    O
he    O
was    O
taking    O
what    O
were    O
the    O
new    O
atypical    B-Sedative104166553
antipsychotic    I-Sedative104166553
of    O
the    O
time    O
period    O
.    O

He    O
was    O
among    O
the    O
first    O
to    O
demonstrate    O
co    O
-    O
transmission    O
in    O
the    O
1970s    O
and    O
also    O
played    O
a    O
pivotal    O
role    O
in    O
developing    O
the    O
atypical    B-Sedative104166553
antipsychotic    I-Sedative104166553
,    O
aripiprazole    B-Sedative104166553
.    O

Pimavanserin    O
,    O
sold    O
under    O
the    O
brand    O
name    O
Nuplazid    O
,    O
is    O
an    O
atypical    B-Sedative104166553
antipsychotic    I-Sedative104166553
which    O
is    O
approved    O
for    O
the    O
treatment    O
of    O
Parkinson    O
's    O
disease    O
psychosis    O
and    O
is    O
also    O
under    O
development    O
for    O
the    O
treatment    O
of    O
schizophrenia    O
,    O
agitation    O
,    O
and    O
major    O
depressive    O
disorder    O
.    O

:    O
N05AF02    O
Clopenthixol    B-Sedative104166553

It    O
is    O
the    O
"    O
cis    O
"-    O
isomer    O
of    O
clopenthixol    B-Sedative104166553
(    O
Sordinol    O
,    O
Ciatyl    O
)    O
.    O

Piperacetazine    B-Sedative104166553
(Quide)    I-Sedative104166553
is    O
an    O
antipsychotic    O
prodrug    O
,    O
most    O
notably    O
used    O
for    O
schizophrenia    O
.    O

BINA    B-Sedative104166553
:    O
potent    O
;    O
modest    O
ago    O
-    O
allosteric    O
modulator    O
;    O
robust    O
in    O
-    O
vivo    O
activity    O
.    O

BL-1020    B-Sedative104166553
â    O
orally    O
available    O
GABA    O
-    O
enhanced    O
antipsychotic    O
for    O
treatment    O
of    O
schizophrenia    O

Nortetrazepam    B-Sedative104166553
is    O
a    O
drug    O
which    O
is    O
a    O
benzodiazepine    O
derivative    O
,    O
one    O
of    O
the    O
major    O
metabolites    O
of    O
tetrazepam    B-Sedative104166553
.    O

Z-drug    B-Sedative104166553
are    O
a    O
group    O
of    O
drugs    O
with    O
effects    O
generally    O
similar    O
to    O
benzodiazepines    O
,    O
which    O
are    O
used    O
in    O
the    O
treatment    O
of    O
insomnia    O
.    O

These    O
include    O
the    O
nonbenzodiazepine    B-Sedative104166553
Z-drugs    B-Sedative104166553
,    O
which    O
have    O
a    O
similar    O
mechanism    O
of    O
action    O
.    O

The    O
authors    O
also    O
warned    O
of    O
the    O
similarities    O
in    O
pharmacology    O
and    O
mechanism    O
of    O
action    O
of    O
the    O
newer    O
nonbenzodiazepine    B-Sedative104166553
Z    B-Sedative104166553
drugs    I-Sedative104166553
.    O

Originally    O
developed    O
by    O
Actelion    O
,    O
from    O
2007    O
almorexant    O
was    O
being    O
reported    O
as    O
a    O
potential    O
blockbuster    O
drug    O
,    O
as    O
its    O
novel    O
mechanism    O
of    O
action    O
(    O
orexin    O
receptor    O
antagonism    O
)    O
was    O
thought    O
to    O
produce    O
better    O
quality    O
sleep    O
and    O
fewer    O
side    O
effects    O
than    O
the    O
traditional    O
benzodiazepines    O
and    O
Z-drug    B-Sedative104166553
which    O
dominated    O
the    O
multibillion    O
-    O
dollar    O
insomnia    O
medication    O
market    O
.    O

This    O
has    O
also    O
been    O
recorded    O
in    O
non    O
-    O
benzodiazapine    O
sedatives    O
or    O
"    O
z-drug    B-Sedative104166553
"    O
which    O
act    O
on    O
the    O
same    O
set    O
of    O
receptors    O
;    O
such    O
as    O
zolpidem    O
(    O
also    O
known    O
as    O
Ambien    O
)    O
,    O
eszopiclone    O
(    O
also    O
known    O
as    O
Lunesta    O
)    O
,    O
and    O
zopiclone    B-Sedative104166553
(    O
also    O
known    O
by    O
brand    O
names    O
Imovane    O
and    O
Zimovane    O
)    O
.    O

Amitriptyline/perphenazine    B-Sedative104166553
(    O
Duo-Vil    B-Sedative104166553
,    O
Etrafon    B-Sedative104166553
,    O
Triavil    B-Sedative104166553
,    O
Triptafen    B-Sedative104166553
)    O
is    O
a    O
formulation    O
that    O
contains    O
the    O
tricyclic    O
antidepressant    O
amitriptyline    O
and    O
the    O
medium    O
-    O
potency    O
typical    B-Sedative104166553
(first-generation)    I-Sedative104166553
antipsychotic    I-Sedative104166553
,    O
perphenazine    O
.    O

:    O
N05AB10    O
Perazine    B-Sedative104166553

Mebicar    B-Sedative104166553

Escitalopram    B-Sedative104166553
(    O
Lexapro    O
)    O
,    O
SSRI    O

Selective    O
serotonin    O
reuptake    O
inhibitors    O
(    O
SSRIs    O
)    O
,    O
such    O
as    O
sertraline    O
(    O
Zoloft    O
,    O
Lustral    O
)    O
,    O
escitalopram    B-Sedative104166553
(    O
Lexapro    O
,    O
Cipralex    O
)    O
,    O
fluoxetine    O
(    O
Prozac    O
)    O
,    O
paroxetine    O
(    O
Seroxat    O
)    O
,    O
and    O
citalopram    B-Sedative104166553
,    O
are    O
the    O
primary    O
medications    O
considered    O
,    O
due    O
to    O
their    O
relatively    O
mild    O
side    O
effects    O
and    O
broad    O
effect    O
on    O
the    O
symptoms    O
of    O
depression    O
and    O
anxiety    O
,    O
as    O
well    O
as    O
reduced    O
risk    O
in    O
overdose    O
,    O
compared    O
to    O
their    O
older    O
tricyclic    O
alternatives    O
.    O

A    O
double    O
-    O
blinded    O
,    O
placebo    O
-    O
controlled    O
trial    O
focusing    O
on    O
women    O
with    O
major    O
depressive    O
disorder    O
found    O
that    O
daily    O
creatine    O
supplementation    O
adjunctive    O
to    O
escitalopram    B-Sedative104166553
was    O
more    O
effective    O
than    O
escitalopram    O
alone    O
.    O

Escitalopram    B-Sedative104166553

Pharmacological    O
interventions    O
include    O
the    O
use    O
of    O
SSRIs    O
,    O
such    O
as    O
fluvoxamine    O
,    O
citalopram    B-Sedative104166553
,    O
escitalopram    B-Sedative104166553
,    O
and    O
naltrexone    O

Many    O
other    O
SSRI    O
antidepressants    O
are    O
fluorinated    O
organics    O
,    O
including    O
Celexa    B-Sedative104166553
,    O
Luvox    O
,    O
and    O
Lexapro    B-Sedative104166553
.    O

It    O
also    O
binds    O
to    O
the    O
allosteric    O
site    O
of    O
the    O
serotonin    O
transporter    O
,    O
similarly    O
,    O
but    O
less    O
potently    O
,    O
than    O
escitalopram    B-Sedative104166553
.    O

Escitalopram    B-Sedative104166553

A    O
brand    O
name    O
for    O
Escitalopram    B-Sedative104166553

Yangonin    B-Sedative104166553

Greg    B-Sedative104166553
Johnson    I-Sedative104166553
(rugby    I-Sedative104166553
league)    I-Sedative104166553
(    O
born    O
1990    O
)    O
,    O
professional    O
rugby    O
player    O

mexazolam    B-Sedative104166553
(    O
INN    O
)    O

Opipramol    B-Sedative104166553
,    O
sold    O
under    O
the    O
brand    O
name    O
Insidon    B-Sedative104166553
among    O
others    O
,    O
is    O
an    O
anxiolytic    O
and    O
antidepressant    O
which    O
is    O
used    O
throughout    O
Europe    O
.    O

The    O
antidepressants    O
that    O
do    O
not    O
act    O
through    O
the    O
monoamine    O
system    O
,    O
such    O
as    O
tianeptine    O
and    O
opipramol    B-Sedative104166553
,    O
have    O
been    O
known    O
for    O
a    O
long    O
time    O
.    O

Intranasal    O
esketamine    B-Sedative104166553
,    O
an    O
enantiomer    O
of    O
ketamine    O
,    O
is    O
in    O
the    O
final    O
stages    O
of    O
development    O
for    O
depression    O
.    O

NMDA    O
receptor    O
antagonists    O
like    O
ketamine    O
,    O
esketamine    B-Sedative104166553
(    O
JNJ-54135419    O
)    O
,    O
rapastinel    O
(    O
GLYX-13    O
)    O
,    O
apimostinel    O
(    O
NRX-1074    O
)    O
,    O
4-chlorokynurenine    O
(    O
AV-101    O
)    O
,    O
traxoprodil    O
(    O
CP-101606    O
)    O
,    O
rislenemdaz    O
(    O
CERC-301    O
,    O
MK-0657    O
)    O
,    O
nitrous    O
oxide    O
,    O
and    O
others    O

ketamine    O
(    O
dissociative    O
)    O
and    O
its    O
stereoisomer    O
esketamine    B-Sedative104166553

Buthalital    B-Sedative104166553
sodium    I-Sedative104166553
(    O
INN    O
;    O
Bayinal    B-Sedative104166553
,    O
Baytinal    B-Sedative104166553
,    O
Thialbutal    B-Sedative104166553
,    O
Transithal    B-Sedative104166553
,    O
Ulbreval    B-Sedative104166553
)    O
,    O
or    O
buthalitone    B-Sedative104166553
sodium    I-Sedative104166553
(    O
BAN    O
)    O
,    O
is    O
a    O
barbiturate    O
derivative    O
which    O
was    O
under    O
development    O
as    O
a    O
short    O
-    O
acting    O
anesthetic    O
.    O

Taken    O
together    O
,    O
the    O
findings    O
that    O
barbiturates    O
potentiate    O
inhibitory    O
GABAA    O
receptors    O
and    O
inhibit    O
excitatory    O
AMPA    O
receptors    O
can    O
explain    O
the    O
superior    O
CNS    O
-    O
depressant    O
effects    O
of    O
these    O
agents    O
to    O
alternative    O
GABA    O
potentiating    O
agents    O
such    O
as    O
benzodiazepines    O
and    O
quinazolinone    B-Sedative104166553
.    O

Fluproquazone    O
(    O
trade    O
name    O
Tormosyl    O
,    O
RF    O
46    O
-    O
790    O
)    O
was    O
a    O
quinazolinone    B-Sedative104166553
derivative    O
with    O
potent    O
analgesic    O
,    O
antipyretic    O
,    O
and    O
anti    O
-    O
inflammatory    O
effects    O
discovered    O
by    O
Sandoz    O
.    O

Diproqualone    B-Sedative104166553
is    O
a    O
quinazolinone    B-Sedative104166553
class    O
GABAergic    O
and    O
is    O
an    O
analogue    O
of    O
methaqualone    O
developed    O
in    O
the    O
late    O
1950s    O
by    O
a    O
team    O
at    O
Nogentaise    O
de    O
Produits    O
Chimique    O
.    O

Adatanserin    B-Sedative104166553

Gepirone    B-Sedative104166553
is    O
an    O
antidepressant    O
and    O
anxiolytic    O
drug    O
of    O
the    O
azapirone    O
group    O
that    O
was    O
synthesized    O
by    O
Bristol    O
-    O
Myers    O
Squibb    O
in    O
1986    O
and    O
has    O
been    O
under    O
development    O
for    O
the    O
treatment    O
of    O
depression    O
but    O
has    O
yet    O
to    O
be    O
marketed    O
.    O

It    O
has    O
been    O
under    O
development    O
in    O
the    O
U.S.    O
in    O
an    O
extended    O
release    O
form    O
(    O
referred    O
to    O
as    O
gepirone    B-Sedative104166553
ER    I-Sedative104166553
)    O
,    O
but    O
despite    O
completing    O
phase    O
III    O
clinical    O
trials    O
and    O
demonstrating    O
efficacy    O
,    O
it    O
has    O
been    O
rejected    O
multiple    O
times    O
by    O
the    O
Food    O
and    O
Drug    O
Administration    O
(    O
FDA    O
)    O
during    O
the    O
drug    O
approval    O
process    O
.    O

Carpipramine    B-Sedative104166553

:    O
R06AD01    O
Alimemazine    B-Sedative104166553

Alimemazine    B-Sedative104166553

Zometapine    B-Sedative104166553
(    O
CI-781    B-Sedative104166553
)    O
is    O
an    O
antidepressant    O
drug    O
which    O
is    O
a    O
pyrazolodiazepine    O
derivative    O
.    O

Higher    O
doses    O
of    O
the    O
patch    O
and    O
oral    O
formulations    O
,    O
whether    O
in    O
combination    O
with    O
the    O
older    O
non    O
-    O
selective    O
MAOIs    O
or    O
in    O
combination    O
with    O
the    O
reversible    O
MAO    O
-    O
A    O
inhibitor    O
moclobemide    B-Sedative104166553
,    O
require    O
a    O
low    O
tyramine    O
diet    O
.    O

moclobemide    B-Sedative104166553

:    O
moclobemide    B-Sedative104166553
(    O
antidepressant    O
)    O

Moclobemide    B-Sedative104166553
.    O
Moclobemide    O
is    O
advised    O
not    O
to    O
be    O
started    O
until    O
at    O
least    O
one    O
week    O
after    O
treatment    O
with    O
TCAs    O
is    O
discontinued    O
.    O

Compared    O
to    O
the    O
reversible    O
MAOI    O
antidepressant    O
drug    O
moclobemide    B-Sedative104166553
,    O
significantly    O
more    O
impairment    O
of    O
vigilance    O
occurs    O
with    O
trazodone    O
.    O

However    O
,    O
evidence    O
indicates    O
that    O
harmala    O
alkaloids    O
act    O
only    O
on    O
MAO    O
-    O
A    O
,    O
in    O
a    O
reversible    O
way    O
similar    O
to    O
moclobemide    B-Sedative104166553
(    O
an    O
antidepressant    O
that    O
does    O
not    O
require    O
dietary    O
restrictions    O
)    O
.    O

Naluzotan    B-Sedative104166553
â    O
antidepressant    O

Talampanel    B-Sedative104166553

Bifeprunox    B-Sedative104166553
â    O
Antipsychotic    O

:    O
QN05AD90    O
Azaperone    B-Sedative104166553

Tends    O
to    O
produce    O
a    O
moderate    O
amount    O
of    O
sedation    O
,    O
less    O
than    O
clozapine    O
and    O
chlorpromazine    O
but    O
more    O
than    O
aripiprazole    B-Sedative104166553
,    O
amisulpride    O
,    O
paliperidone    O
and    O
sertindole    B-Sedative104166553
and    O
approximately    O
that    O
of    O
quetiapine    O
and    O
risperidone    O
.    O

Sertindole    B-Sedative104166553

Long-term    B-Sedative104166553
use    I-Sedative104166553
of    I-Sedative104166553
benzodiazepines    I-Sedative104166553
leads    O
to    O
increasing    O
physical    O
and    O
mental    O
health    O
problems    O
,    O
and    O
as    O
a    O
result    O
,    O
discontinuation    O
is    O
recommended    O
for    O
many    O
long    O
-    O
term    O
users    O
.    O

Continued    B-Sedative104166553
use    I-Sedative104166553
despite    I-Sedative104166553
harmful    I-Sedative104166553
consequences    I-Sedative104166553

Long-term    B-Sedative104166553
effects    I-Sedative104166553
of    I-Sedative104166553
benzodiazepines    I-Sedative104166553

Long-term    B-Sedative104166553
effects    I-Sedative104166553
of    I-Sedative104166553
benzodiazepines    I-Sedative104166553

While    O
in    O
the    O
hospital    O
for    O
treatment    O
,    O
Green    O
was    O
diagnosed    O
with    O
"    O
major    O
bipolar    O
depression    O
with    O
suicidal    O
impulses    O
"    O
and    O
placed    O
on    O
Prozac    O
,    O
Tranxene    B-Sedative104166553
,    O
and    O
Klonopin    B-Sedative104166553
.    O

Long    O
-    O
term    O
use    O
of    O
diazepam    O
for    O
the    O
management    O
of    O
epilepsy    O
is    O
not    O
recommended    O
;    O
however    O
,    O
a    O
subgroup    O
of    O
individuals    O
with    O
treatment    O
-    O
resistant    O
epilepsy    O
benefit    O
from    O
long    O
-    O
term    O
benzodiazepines    O
,    O
and    O
for    O
such    O
individuals    O
,    O
clorazepate    B-Sedative104166553
has    O
been    O
recommended    O
due    O
to    O
its    O
slower    O
onset    O
of    O
tolerance    O
to    O
the    O
anticonvulsant    O
effects    O
.    O

Other    O
classical    O
benzodiazepines    O
include    O
chlordiazepoxide    O
,    O
clonazepam    B-Sedative104166553
,    O
lorazepam    O
,    O
oxazepam    O
,    O
nitrazepam    O
,    O
temazepam    O
,    O
flurazepam    O
,    O
bromazepam    O
,    O
and    O
clorazepate    B-Sedative104166553
.    O

:    O
N05AL04    O
Remoxipride    B-Sedative104166553

:    O
N01AG01    O
Narcobarbital    B-Sedative104166553

Lurasidone    B-Sedative104166553
(    O
trade    O
name    O
Latuda    B-Sedative104166553
)    O
is    O
an    O
atypical    B-Sedative104166553
antipsychotic    I-Sedative104166553
developed    O
by    O
Dainippon    O
Sumitomo    O
Pharma    O
and    O
marketed    O
by    O
Sunovion    O
in    O
the    O
U.S.    O

Lurasidone    B-Sedative104166553
(    O
Latuda    O
)    O

Lurasidone    B-Sedative104166553

Lurasidone    B-Sedative104166553

NGD-4715    B-Sedative104166553

Avizafone    B-Sedative104166553

prazepam    B-Sedative104166553

Benzodiazepines    O
with    O
a    O
half    O
-    O
life    O
of    O
more    O
than    O
24    O
hours    O
include    O
chlordiazepoxide    O
,    O
diazepam    O
,    O
clobazam    B-Sedative104166553
,    O
clonazepam    B-Sedative104166553
,    O
chlorazepinic    O
acid    O
,    O
ketazolam    B-Sedative104166553
,    O
medazepam    B-Sedative104166553
,    O
nordazepam    B-Sedative104166553
,    O
and    O
prazepam    B-Sedative104166553
.    O

Ro48-8684    B-Sedative104166553
is    O
a    O
water    O
-    O
soluble    O
benzodiazepine    O
derivative    O
developed    O
by    O
Hoffman    O
-    O
LaRoche    O
in    O
the    O
1990s    O
,    O
which    O
was    O
designed    O
along    O
with    O
Ro48-6791    B-Sedative104166553
as    O
an    O
improved    O
replacement    O
for    O
midazolam    O
,    O
but    O
ultimately    O
proved    O
to    O
have    O
little    O
advantages    O
over    O
the    O
parent    O
drug    O
and    O
has    O
not    O
been    O
introduced    O
into    O
clinical    O
practice    O
.    O

#    O
Halazepam    B-Sedative104166553

halazepam    B-Sedative104166553

Tolpiprazole    B-Sedative104166553
(    O
tranquilizer    O
)    O

Azacyclonol    O
(    O
trade    O
names    O
Ataractan    O
,    O
Calmeran    O
,    O
Frenoton    O
,    O
Frenquel    O
,    O
Psychosan    O
)    O
,    O
also    O
known    O
as    O
Î³-pipradrol    O
,    O
is    O
a    O
drug    O
which    O
is    O
an    O
ataractive    B-Sedative104166553
;    O
an    O
agent    O
which    O
diminishes    O
hallucinations    O
in    O
psychotic    O
individuals    O
.    O

FGIN-143    B-Sedative104166553

Sigmodal    B-Sedative104166553
(    O
Rectidon    O
)    O
is    O
a    O
barbiturate    O
derivative    O
.    O

Pizotifen    B-Sedative104166553

Its    O
origin    O
depended    O
on    O
the    O
well    O
-    O
known    O
fact    O
that    O
a    O
divalent    O
sulfur    O
is    O
roughly    O
equivalent    O
to    O
a    O
vinyl    O
group    O
(    O
cf    O
methiopropamine    O
,    O
sufentanil    O
,    O
pizotyline    B-Sedative104166553
etc    O
.    O
)    O
.    O

There    O
is    O
tentative    O
evidence    O
for    O
the    O
medication    O
flupentixol    B-Sedative104166553
;    O
however    O
,    O
greater    O
study    O
is    O
required    O
before    O
it    O
can    O
be    O
recommended    O
.    O

Between    O
March    O
and    O
April    O
1991    O
,    O
Charnley    O
experimented    O
with    O
varying    O
dosages    O
of    O
his    O
medication    O
-    O
Depixol    B-Sedative104166553
and    O
Tryptisol    O
-    O
painting    O
a    O
self    O
-    O
portrait    O
each    O
day    O
that    O
reflected    O
how    O
his    O
concept    O
of    O
'    O
self    O
'    O
changed    O
with    O
the    O
illness    O
.    O

Flupenthixol    B-Sedative104166553
(    O
Fluanxol    O
)    O

He    O
scored    O
23    O
tries    O
in    O
68    O
appearances    O
for    O
the    O
club    O
,    O
and    O
took    O
part    O
in    O
the    O
Clash    B-Sedative104166553
of    I-Sedative104166553
the    I-Sedative104166553
Codes    I-Sedative104166553
match    O
against    O
Bath    O
,    O
scoring    O
two    O
tries    O
in    O
the    O
match    O
played    O
under    O
rugby    O
union    O
rules    O
.    O

Gaboxadol    B-Sedative104166553

Gaboxadol    B-Sedative104166553

Afloqualone    B-Sedative104166553

lorbamate    B-Sedative104166553
(    O
INN    O
)    O

naranol    B-Sedative104166553
(    O
INN    O
)    O

ROD-188    B-Sedative104166553
is    O
a    O
sedative    O
drug    O
that    O
was    O
structurally    O
derived    O
from    O
the    O
GABAA    O
antagonist    O
bicuculline    O
by    O
a    O
team    O
at    O
Roche    O
.    O

Dacrycarpus    O
imbricatus    O
-    O
Daewoo    O
Precision    O
Industries    O
K2    O
-    O
Daily    O
Post    O
(    O
Fiji    O
)    O
-    O
Keni    O
DAKUIDREKETI    O
-    O
Joe    O
DAKUITOGA    O
-    O
Dakuwaqa    O
-    O
Dama    O
River    O
-    O
Dance    O
in    O
Rotuma    O
-    O
Danube    O
(    O
ship    O
)    O
-    O
Quazi    O
Golam    O
DASTGIR    O
-    O
Daucina    O
-    O
Jone    O
DAUNIVUCU    O
-    O
Waisea    O
DAVETA    O
-    O
Samuela    O
DAVETAWALU    O
-    O
Vilimaina    O
DAVU    O
-    O
Davuilevu    O
-    O
Dawacumu    O
River    O
-    O
Dawasamu    O
River    O
-    O
Daylight    O
saving    O
time    O
in    O
Fiji    O
-    O
Noor    O
DEAN    O
-    O
Deans    O
Trophy    O
-    O
Degei    O
-    O
Apisalome    O
DEGEI    O
-    O
Degeneriaceae    O
-    O
Jone    O
DELAI    O
-    O
DELAILOA    O
-    O
Nelson    O
DELAILOMALOMA    O
-    O
Iliesa    O
DELANA    O
-    O
Vilimoni    O
DELASAU    O
-    O
Demographics    O
of    O
Fiji    O
-    O
Denarau    O
Island    O
-    O
Roshika    O
DEO    O
-    O
Vishnu    O
DEO    O
-    O
Andrew    O
DEOKI    O
-    O
Ram    O
Narayan    O
DEOKI    O
-    O
Deorbit    O
of    O
Mir    O
-    O
Derek    O
DERENALAGI    O
-    O
James    O
Herman    O
DE    O
RICCI    O
-    O
Desmethoxyyangonin    O
-    O
Sir    O
William    O
DES    O
VÅUX    O
-    O
Deuba    O
River    O
-    O
DEUCE    O
-    O
Graham    O
DEWES    O
-    O
Dhantal    O
-    O
Digicel    O
Cup    O
-    O
Laisa    O
DIGITAKI    O
-    O
Dihydrokavain    B-Sedative104166553
-    O
Dihydromethysticin    B-Sedative104166553
-    O
Ratu    O
Josefa    O
DIMURI    O
-    O
Larry    O
Miles    O
DINGER    O
-    O
Diospyros    O
fasciculosa    O
-    O
Diplomatic    O
missions    O
in    O
Fiji    O
,    O
list    O
of    O
-    O
Diplomatic    O
missions    O
of    O
Fiji    O
,    O
list    O
of    O
-    O
Diplomatic    O
relations    O
of    O
Fiji    O
-    O
Director    O
of    O
Public    O
Prosecutions    O
(    O
Fiji    O
)    O
-    O
Iowane    O
DIVAVESI    O
-    O
Manoa    O
DOBUI    O
-    O
Manilal    O
DOCTOR    O
-    O
Dodonu    O
ni    O
Taukei    O
-    O
Keni    O
DOIDOI    O
-    O
Vyacheslav    O
DOLGOV    O
-    O
Dominion    O
of    O
Fiji    O
-    O
Isoa    O
DOMOLAILAI    O
-    O
Sam    O
DOMONI    O
-    O
William    O
Earnest    O
DONNELLY    O
-    O
Alifereti    O
DOVIVERATA    O
-    O
Brian    O
Andre    O
DOYLE    O
-    O
Drakaniwai    O
River    O
-    O
Dranivia    O
-    O
Misaele    O
DRAUNIBAKA    O
-    O
Savenaca    O
DRAUNIDALO    O
-    O
Tupou    O
DRAUNIDALO    O
-    O
Dravuni    O
-    O
Drawa    O
River    O
-    O
Dreketi    O
F.C.    O
-    O
Dreketi    O
River    O
-    O
Pita    O
DRITI    O
-    O
Asaeli    O
DRIU    O
-    O
Moses    O
DRIVER    O
-    O
Ema    O
DRUAVESI    O
-    O
Hannah    O
DUDLEY    O
-    O
Dudley    O
High    O
School    O
-    O
Alfred    O
DUFTY    O
-    O
Colin    O
DUFTY    O
-    O
Francis    O
Herbert    O
DUFTY    O
-    O
Adi    O
Litia    O
Mara    O
DUGDALE    O
-    O
Maciu    O
DUNADAMU    O
-    O
Shanti    O
DUT    O
-    O
Yogendra    O
DUTT    O
-    O
Iliesa    O
DUVULOCO    O
-    O
Lagi    O
DYER    O
-    O
Adi    O
Senimili    O
DYER    O

ciclotizolam    B-Sedative104166553
(    O
INN    O
)    O

Flutoprazepam    B-Sedative104166553
(    O
Restas    B-Sedative104166553
)    O
is    O
a    O
drug    O
which    O
is    O
a    O
benzodiazepine    O
.    O

The    O
commander    O
's    O
capacity    O
for    O
analysis    O
and    O
critical    O
assessment    O
of    O
the    O
situation    O
were    O
possibly    O
limited    O
as    O
a    O
result    O
of    O
the    O
effects    O
of    O
the    O
benzodiazepine    O
drug    O
phenazepam    B-Sedative104166553
found    O
in    O
his    O
muscle    O
tissue    O
.    O

Pack    O
of    O
Phenazepam    B-Sedative104166553
,    O
found    O
in    O
Moldovan    O
pilot    O
Pavel    O
Gruzin    O
's    O
crew    O
bag    O
..    O

Tolufazepam    B-Sedative104166553
is    O
a    O
drug    O
that    O
is    O
a    O
benzodiazepine    O
derivative    O
.    O

Clazolam    B-Sedative104166553
(    O
SAH-1123    B-Sedative104166553
)    O
,    O
also    O
referred    O
to    O
as    O
isoquinazepon    B-Sedative104166553
,    O
is    O
a    O
drug    O
which    O
is    O
a    O
fused    O
benzodiazepine    O
and    O
tetrahydroisoquinoline    O
derivative    O
.    O

Thus    O
,    O
TSPO    O
ligands    O
such    O
as    O
emapunil    O
(    O
XBD-173    O
)    O
or    O
alpidem    B-Sedative104166553
have    O
been    O
proposed    O
to    O
be    O
useful    O
as    O
potential    O
anxiolytics    O
which    O
may    O
have    O
less    O
addiction    O
-    O
based    O
side    O
effects    O
than    O
traditional    O
benzodiazepine    O
-    O
type    O
drugs    O
.    O
,    O
though    O
toxicity    O
side    O
-    O
effects    O
remain    O
a    O
significant    O
barrier    O
in    O
drug    O
development    O
.    O

Alpidem    B-Sedative104166553

Thiethylperazine    B-Sedative104166553
(    O
Torecan    B-Sedative104166553
)    O
is    O
an    O
antiemetic    O
of    O
the    O
phenothiazine    O
class    O
.    O

Many    O
drugs    O
that    O
contain    O
amines    O
are    O
provided    O
as    O
the    O
maleate    O
acid    O
salt    O
,    O
e.g.    O
carfenazine    O
,    O
chlorpheniramine    O
,    O
pyrilamine    O
,    O
methylergonovine    O
,    O
and    O
thiethylperazine    B-Sedative104166553
.    O

ketazolam    B-Sedative104166553

Benzodiazepines    O
with    O
a    O
half    O
-    O
life    O
of    O
more    O
than    O
24    O
hours    O
include    O
chlordiazepoxide    O
,    O
diazepam    O
,    O
clobazam    B-Sedative104166553
,    O
clonazepam    B-Sedative104166553
,    O
chlorazepinic    O
acid    O
,    O
ketazolam    B-Sedative104166553
,    O
medazepam    B-Sedative104166553
,    O
nordazepam    B-Sedative104166553
,    O
and    O
prazepam    B-Sedative104166553
.    O

fludiazepam    B-Sedative104166553

cyprazepam    B-Sedative104166553
(    O
INN    O
)    O

Ted    O
takes    O
him    O
home    O
,    O
and    O
Blake    O
gets    O
him    O
to    O
try    O
GHB    B-Sedative104166553
,    O
with    O
disastrous    O
results    O
.    O

GMHC    O
pulled    O
the    O
plug    O
after    O
the    O
1998    O
fundraiser    O
after    O
one    O
man    O
died    O
on    O
Fire    O
Island    O
of    O
an    O
overdose    O
of    O
the    O
drug    O
gamma    B-Sedative104166553
hydroxy    I-Sedative104166553
butyrate    I-Sedative104166553
(    O
GHB    O
)    O
the    O
evening    O
before    O
the    O
party    O
and    O
21    O
revelers    O
were    O
arrested    O
for    O
drug    O
possession    O
.    O

The    O
controlled    O
drug    O
which    O
it    O
was    O
alleged    O
1,4-B    O
was    O
substantially    O
similar    O
to    O
was    O
gamma-hydroxybutyrate    B-Sedative104166553
(    O
GHB    O
)    O
.    O

Substances    O
that    O
may    O
cause    O
this    O
toxidrome    O
include    O
anticonvulsants    O
,    O
barbiturates    O
,    O
benzodiazepines    O
,    O
gamma-Hydroxybutyric    B-Sedative104166553
acid    I-Sedative104166553
,    O
Methaqualone    O
,    O
and    O
ethanol    O
.    O

gamma-hydroxybutyric    B-Sedative104166553
acid    I-Sedative104166553
(    O
GHB    O
)    O

David    O
Amess    O
,    O
the    O
Conservative    O
Member    O
of    O
Parliament    O
for    O
Basildon    O
,    O
was    O
fooled    O
into    O
filming    O
an    O
elaborate    O
video    O
warning    O
against    O
the    O
dangers    O
of    O
this    O
drug    O
,    O
and    O
went    O
as    O
far    O
as    O
to    O
ask    O
a    O
question    O
about    O
"    O
Cake    O
"    O
in    O
the    O
UK    O
Parliament    O
,    O
alongside    O
real    O
substances    O
khat    O
and    O
gamma-hydroxybutyric    B-Sedative104166553
acid    I-Sedative104166553
.    O

Valeric    O
acid    O
appears    O
similar    O
in    O
structure    O
to    O
GHB    B-Sedative104166553
and    O
the    O
neurotransmitter    O
GABA    O
in    O
that    O
it    O
is    O
a    O
short    O
-    O
chain    O
carboxylic    O
acid    O
,    O
although    O
it    O
lacks    O
the    O
alcohol    O
and    O
amine    O
functional    O
groups    O
that    O
contribute    O
to    O
the    O
biological    O
activities    O
of    O
GHB    O
and    O
GABA    O
,    O
respectively    O
.    O

The    O
medical    O
examiner    O
stated    O
that    O
Tang    O
was    O
found    O
with    O
320    O
wounds    O
from    O
blunt    O
force    O
trauma    O
(    O
not    O
including    O
bruises    O
)    O
and    O
with    O
high    O
doses    O
of    O
the    O
drug    O
GHB    B-Sedative104166553
in    O
her    O
system    O
,    O
together    O
with    O
trace    O
amounts    O
of    O
cocaine    O
.    O

The    O
Emergency    O
Department    O
was    O
one    O
of    O
the    O
first    O
in    O
NSW    O
to    O
implement    O
a    O
PECC    O
(    O
Psychiatric    O
Emergency    O
Care    O
Centre    O
)    O
,    O
in    O
response    O
to    O
the    O
high    O
number    O
of    O
people    O
with    O
a    O
mental    O
illness    O
residing    O
in    O
the    O
inner    O
suburbs    O
of    O
Sydney    O
,    O
as    O
well    O
as    O
the    O
increasing    O
incidence    O
of    O
people    O
affected    O
by    O
illegal    O
,    O
psychoactive    O
drugs    O
such    O
as    O
heroin    O
,    O
GHB    B-Sedative104166553
and    O
crystal    O
meth    O
.    O

4-Hydroxy-4-methylpentanoic    O
acid    O
(    O
UMB68    O
)    O
is    O
a    O
tertiary    O
alcohol    O
,    O
similar    O
in    O
structure    O
to    O
the    O
drug    O
GHB    B-Sedative104166553
.    O

The    O
chemical    O
gamma-hydroxybutyric    B-Sedative104166553
acid    I-Sedative104166553
(    O
GHB    O
)    O
has    O
been    O
studied    O
to    O
increase    O
SWS    O
.    O

GHB    B-Sedative104166553

This    O
includes    O
drugs    O
less    O
immediately    O
classed    O
to    O
a    O
slowing    O
of    O
the    O
metabolism    O
such    O
as    O
with    O
GABAergics    O
like    O
GHB    B-Sedative104166553
or    O
glutamatergic    O
antagonists    O
like    O
PCP    O
or    O
ketamine    O
.    O

For    O
instance    O
,    O
GHB    B-Sedative104166553
,    O
a    O
naturally    O
occurring    O
substance    O
in    O
the    O
central    O
nervous    O
system    O
is    O
considered    O
a    O
drug    O
,    O
and    O
is    O
illegal    O
in    O
many    O
countries    O
,    O
while    O
nicotine    O
is    O
not    O
officially    O
considered    O
a    O
drug    O
in    O
most    O
countries    O
.    O

Benjie    O
breaks    O
his    O
sobriety    O
,    O
getting    O
high    O
on    O
GHB    B-Sedative104166553
,    O
and    O
carelessly    O
shoots    O
the    O
dog    O
of    O
his    O
only    O
friend    O
.    O

Also    O
recovered    O
in    O
the    O
operation    O
were    O
synthetic    O
materials    O
,    O
various    O
drug    O
paraphernalia    O
and    O
a    O
manual    O
on    O
making    O
illegal    O
drugs    O
such    O
as    O
methamphetamine    O
hydrochloride    O
or    O
shabu    O
,    O
D    O
-    O
lysergic    O
acid    O
diethylamide    O
and    O
gamma-Hydroxybutyric    B-Sedative104166553
acid    I-Sedative104166553
(    O
GHB    O
)    O
or    O
liquid    O
ecstasy    O
.    O

Î³-Hydroxybutyraldehyde    O
,    O
also    O
referred    O
to    O
as    O
GHBAL    O
,    O
Î³-hydroxybutaldehyde    O
or    O
Î³-hydroxybutanal    O
,    O
is    O
a    O
chemical    O
intermediate    O
in    O
the    O
biosynthesis    O
of    O
the    O
neurotransmitter    O
Î³-hydroxybutyric    B-Sedative104166553
acid    I-Sedative104166553
(    O
GHB    O
)    O
from    O
1,4-butanediol    B-Sedative104166553
(    O
1,4-BD    O
)    O
.    O

After    O
sleeping    O
with    O
JJ    O
,    O
Theresa    O
overdoses    O
on    O
marijuana    O
and    O
GHB    B-Sedative104166553
.    O

John    O
follows    O
Hector    O
deeper    O
into    O
circuit    O
scene    O
,    O
using    O
a    O
variety    O
of    O
drugs    O
including    O
Special    O
K    O
,    O
GHB    B-Sedative104166553
,    O
cocaine    O
,    O
crystal    O
meth    O
and    O
,    O
suffering    O
from    O
body    O
dysmorphia    O
despite    O
being    O
in    O
terrific    O
physical    O
shape    O
,    O
anabolic    O
steroids    O
.    O

A    O
toxicology    O
report    O
revealed    O
20    O
mg    O
/    O
mL    O
of    O
GHB    B-Sedative104166553
in    O
his    O
system    O
,    O
which    O
the    O
coroner    O
said    O
did    O
not    O
contribute    O
to    O
Barrier    O
's    O
death    O
.    O

It    O
also    O
directed    O
the    O
United    O
States    O
Sentencing    O
Commission    O
to    O
consider    O
increasing    O
federal    O
sentencing    O
penalties    O
for    O
offenses    O
involving    O
gamma-Hydroxybutyric    B-Sedative104166553
acid    I-Sedative104166553
(    O
GHB    O
)    O
.    O

Some    O
inhibitors    O
include    O
papaverine    O
,    O
PF-2545920    O
,    O
TC    O
-    O
E    O
5005    O
,    O
and    O
tofisopam    B-Sedative104166553
.    O

Hexethal    B-Sedative104166553
(    O
Ortol    B-Sedative104166553
)    O
is    O
a    O
barbiturate    O
derivative    O
invented    O
in    O
the    O
1940s    O
.    O

:    O
N05AX16    O
Brexpiprazole    B-Sedative104166553

Brexpiprazole    B-Sedative104166553

Niaprazine    B-Sedative104166553
(    O
INN    O
)    O
(    O
brand    O
name    O
Nopron    B-Sedative104166553
)    O
is    O
a    O
sedative    O
-    O
hypnotic    O
drug    O
of    O
the    O
phenylpiperazine    O
group    O
.    O

Acaprazine    B-Sedative104166553
â    O
anxiolytic    O

propofol    O
and    O
fospropofol    B-Sedative104166553
(    O
anesthetics    O
)    O

Olanzapine/fluoxetine    B-Sedative104166553

Crotylbarbital    B-Sedative104166553

Tetrabarbital    B-Sedative104166553
(    O
INN    O
;    O
Butysal    B-Sedative104166553
,    O
Butysedal    B-Sedative104166553
,    O
Tetramal    B-Sedative104166553
)    O
is    O
a    O
barbiturate    O
derivative    O
used    O
as    O
a    O
hypnotic    O
.    O

Y-23684    B-Sedative104166553

Methitural    B-Sedative104166553
(    O
INN    O
;    O
Neraval    B-Sedative104166553
,    O
Thiogenal    B-Sedative104166553
)    O
,    O
or    O
methitural    B-Sedative104166553
sodium    I-Sedative104166553
,    O
also    O
known    O
as    O
methioturiate    B-Sedative104166553
,    O
is    O
a    O
barbiturate    O
derivative    O
which    O
was    O
marketed    O
in    O
the    O
1950s    O
in    O
Europe    O
(    O
in    O
Germany    O
and    O
Italy    O
)    O
as    O
an    O
ultra    O
-    O
short    O
-    O
acting    O
intravenous    O
anesthetic    O
.    O

Tasimelteon    B-Sedative104166553

It    O
is    O
in    O
the    O
same    O
class    O
of    O
melatonin    O
receptor    O
agonists    O
as    O
ramelteon    O
and    O
tasimelteon    B-Sedative104166553
.    O

Other    O
cyclopyrrolone    O
drugs    O
include    O
zopiclone    B-Sedative104166553
,    O
pagoclone    O
and    O
suriclone    B-Sedative104166553
.    O

Ageusia    O
can    O
also    O
be    O
caused    O
by    O
medicinal    O
side    O
-    O
effects    O
from    O
antirheumatic    O
drugs    O
such    O
as    O
penicillamine    O
,    O
antiproliferative    O
drugs    O
such    O
as    O
cisplatin    O
,    O
ACE    O
inhibitors    O
,    O
and    O
other    O
drugs    O
including    O
azelastine    O
,    O
clarithromycin    O
,    O
terbinafine    O
,    O
and    O
zopiclone    B-Sedative104166553
.    O

She    O
said    O
that    O
she    O
drank    O
to    O
escape    O
the    O
breakdown    O
of    O
her    O
relationship    O
with    O
Crane    O
,    O
later    O
revealing    O
she    O
also    O
had    O
an    O
addiction    O
to    O
Zopiclone    B-Sedative104166553
sleeping    O
tablets    O
.    O

zopiclone    B-Sedative104166553
(    O
depressant    O
z-drug    B-Sedative104166553
)    O
and    O
its    O
stereoisomer    O
eszopiclone    O

Zopiclone    B-Sedative104166553
(    O
Imovan    O
)    O

Many    O
drivers    O
had    O
blood    O
levels    O
far    O
exceeding    O
the    O
therapeutic    O
dose    O
range    O
,    O
suggesting    O
a    O
high    O
degree    O
of    O
abuse    O
potential    O
for    O
benzodiazepines    O
and    O
zolpidem    O
and    O
zopiclone    B-Sedative104166553
.    O

This    O
has    O
also    O
been    O
recorded    O
in    O
non    O
-    O
benzodiazapine    O
sedatives    O
or    O
"    O
z-drug    B-Sedative104166553
"    O
which    O
act    O
on    O
the    O
same    O
set    O
of    O
receptors    O
;    O
such    O
as    O
zolpidem    O
(    O
also    O
known    O
as    O
Ambien    O
)    O
,    O
eszopiclone    O
(    O
also    O
known    O
as    O
Lunesta    O
)    O
,    O
and    O
zopiclone    B-Sedative104166553
(    O
also    O
known    O
by    O
brand    O
names    O
Imovane    O
and    O
Zimovane    O
)    O
.    O

:    O
N05AL07    O
Levosulpiride    B-Sedative104166553

#    O
Clotiazepam    B-Sedative104166553

clotiazepam    B-Sedative104166553

#    O
Cloxazolam    B-Sedative104166553

cloxazolam    B-Sedative104166553

Many    O
species    O
formerly    O
placed    O
in    O
"    O
Mesembryanthemum    O
"    O
,    O
such    O
as    O
"    O
Dorotheanthus    O
bellidiformis    O
"    O
,    O
"    O
Carpobrotus    O
"    O
spp    O
.    O
and    O
"    O
Sceletium    B-Sedative104166553
"    O
spp    O
.    O
have    O
since    O
been    O
moved    O
into    O
other    O
genera    O
.    O

"    O
Sceletium    B-Sedative104166553
tortuosum    I-Sedative104166553
"    O
,    O
a    O
Southern    O
African    O
succulent    O
with    O
psychoactive    O
properties    O

He    O
starts    O
by    O
driving    O
Scully    O
's    O
car    O
to    O
Nutter    O
's    O
Feed    O
Store    O
in    O
a    O
small    O
town    O
near    O
the    O
abductions    O
,    O
as    O
the    O
human    O
remains    O
contain    O
acepromazine    B-Sedative104166553
,    O
an    O
animal    O
tranquilizer    O
.    O

Acepromazine    B-Sedative104166553
(    O
antipsychotic    O
,    O
secondary    O
mechanism    O
)    O

According    O
to    O
Berdella    O
,    O
he    O
plied    O
Howell    O
with    O
alcohol    O
,    O
Valium    O
and    O
acepromazine    B-Sedative104166553
both    O
in    O
his    O
car    O
and    O
at    O
his    O
house    O
until    O
the    O
youth    O
became    O
unconscious    O
.    O

Acepromazine    B-Sedative104166553
,    O
veterinary    O
sedative    O

:    O
N05BD01    O
Benzoctamine    B-Sedative104166553

thialbarbital    B-Sedative104166553
(    O
INN    O
)    O

Among    O
there    O
are    O
fish    O
,    O
the    O
grey    O
heron    O
,    O
neophyte    O
plants    O
and    O
Orange    B-Sedative104166553
Jewelweed    I-Sedative104166553
(    O
"    O
Impatiens    O
capensis    O
"    O
,    O
in    O
Hagen    O
)    O
.    O

This    O
efficiency    O
makes    O
cleistogamy    O
particularly    O
useful    O
for    O
seed    O
production    O
on    O
unfavorable    O
sites    O
or    O
adverse    O
conditions    O
.    O
"    O
Impatiens    B-Sedative104166553
capensis    I-Sedative104166553
,    O
"    O
for    O
example    O
,    O
has    O
been    O
observed    O
to    O
produce    O
only    O
cleistogamous    O
flowers    O
after    O
being    O
severely    O
damaged    O
by    O
grazing    O
and    O
to    O
maintain    O
populations    O
on    O
unfavorable    O
sites    O
with    O
only    O
cleistogamous    O
flowers    O
.    O

The    O
Chess    O
is    O
also    O
home    O
to    O
a    O
number    O
of    O
invasive    O
alien    O
plant    O
species    O
including    O
Japanese    O
knotweed    O
,    O
Himalayan    O
balsam    O
and    O
Orange    B-Sedative104166553
balsam    I-Sedative104166553
.    O

Hosanna    O
KABAKORO    O
-    O
Kabara    O
-    O
Glenn    O
KABLE    O
-    O
Kadavu    O
fantail    O
-    O
Kadavu    O
Group    O
-    O
Kadavu    O
honeyeater    O
-    O
Kadavu    O
Island    O
-    O
Penaia    O
KADAVULEVU    O
-    O
Kaibu    O
-    O
Simione    O
KAITANI    O
-    O
Kaivalagi    O
-    O
Kaiviti    O
-    O
Sekonaia    O
KALOU    O
-    O
Atunaisa    O
KALOUMAIRAI    O
-    O
KALOUYALEWA    O
-    O
Daren    O
KAMALI    O
-    O
Tomasi    O
KANAILAGI    O
-    O
Kanacea    O
-    O
Kanaka    O
-    O
Ratu    O
Epeli    O
KANAKANA    O
-    O
Kanakas    O
-    O
Malakai    O
KAINIHEWE    O
-    O
Mari    O
KAPI    O
-    O
Kasavu    O
River    O
-    O
Wise    O
KATIVERATA    O
-    O
Kato'aga    O
-    O
Ratu    O
Aisea    O
KATONIVERE    O
-    O
Jonetani    O
KAUKIMOCE    O
-    O
Kaunitoni    O
-    O
Malakai    O
KAUNIVALU    O
-    O
Samuela    O
KAUTOGA    O
-    O
Kava    O
-    O
Kava    O
culture    O
-    O
Kavain    B-Sedative104166553
-    O
Kavalactone    B-Sedative104166553
-    O
Kavula    O
River    O
-    O
"    O
Adi    O
"    O
Salaseini    O
KAVUNONO    O
-    O
Nemani    O
KAVURU    O
-    O
Francis    O
KEAN    O
-    O
Freddy    O
KEIAHO    O
-    O
Kenneth    O
KEITH    O
-    O
Declan    O
KELLY    O
-    O
Nemia    O
KENATALE    O
-    O
Kendrit    O
Shiri    O
Sanatan    O
Dharam    O
Shiv    O
Temple    O
-    O
Ro    O
Teimumu    O
KEPA    O
-    O
Sailosi    O
KEPA    O
-    O
Iliesa    O
KERESONI    O
-    O
Samu    O
KEREVI    O
-    O
Rashit    O
KHAMIDULIN    O
-    O
Tulsi    O
Ram    O
KHELWAN    O
-    O
Shah    O
KIBRIA    O
-    O
Lyons    O
KIERAN    O
-    O
Viliame    O
KIKAU    O
-    O
Kingiodendron    O
platycarpum    O
-    O
Kioa    O
-    O
Kisan    O
Sangh    O
-    O
Arthur    O
KITINAS    O
-    O
Kleinhovia    O
-    O
Meli    O
KOLIAVU    O
-    O
Osea    O
KOLINISAU    O
-    O
George    O
KONROTE    O
-    O
Sevanaia    O
KORO    O
-    O
Koro    O
Airport    O
-    O
Koro    O
Island    O
-    O
Koro    O
-    O
ni    O
-    O
O    O
-    O
Koro    O
Sea    O
-    O
Jimi    O
KOROI    O
-    O
Jokapeci    O
KOROI    O
-    O
Marika    O
KOROIBETE    O
-    O
Kiniviliame    O
KOROIBULEKA    O
-    O
Josua    O
KOROIBULU    O
-    O
Semi    O
KOROILAVESAU    O
-    O
Apisai    O
KOROISAU    O
-    O
Koroivonu    O
River    O
-    O
Korolevu    O
River    O
-    O
Koro    O
-    O
ni    O
-    O
O    O
-    O
Korotasere    O
River    O
-    O
Niumaia    O
KOROVATA    O
-    O
Lesi    O
KOROVAVALA    O
-    O
Korovou    O
-    O
Al    O
KOROVOU    O
-    O
Manu    O
KOROVULAVULA    O
-    O
Korovuli    O
River    O
-    O
Koroyanitu    O
,    O
Mount    O
-    O
Sunia    O
KOTO    O
-    O
Joji    O
KOTOBALAVU    O
-    O
Faiyaz    O
KOYA    O
-    O
Sidiq    O
KOYA    O
-    O
Nailani    O
KRISHAN    O
-    O
James    O
Shri    O
KRISHNA    O
-    O
Roy    O
KRISHNA    O
-    O
Ratu    O
Inoke    O
KUBUABOLA    O
-    O
Ratu    O
Jone    O
KUBUABOLA    O
-    O
Sisa    O
KOYAMAIBOLE    O
-    O
Kubuna    O
Confederacy    O
-    O
Kubuna    O
River    O
-    O
Kula    O
Eco    O
Park    O
-    O
Kulu    O
Bay    O
Resort    O
-    O
Semi    O
KUNATANI    O
-    O
Maleli    O
KUNAVORE    O
-    O
Sadhu    O
KUPPUSWAMI    O
-    O
Jone    O
KURADUADUA    O
-    O
Chris    O
KURIDRANI    O
-    O
Tevita    O
KURIDRANI    O
-    O
Selina    O
KURULECA    O
-    O
Suliasi    O
KURULO    O
-    O
Kundan    O
Singh    O
KUSH    O
-    O
Kya    O
Dilli    O
Kya    O
Lahore    O

Desmethoxyyangonin    O
or    O
5,6-dehydrokawain    O
is    O
one    O
of    O
the    O
six    O
major    O
kavalactone    B-Sedative104166553
found    O
in    O
the    O
"    O
Piper    O
methysticum    O
"    O
(    O
kava    O
)    O
plant    O
.    O

Kavain    B-Sedative104166553
is    O
the    O
main    O
kavalactone    B-Sedative104166553
found    O
mostly    O
in    O
the    O
roots    O
of    O
the    O
kava    O
plant    O
.    O

Fosazepam    B-Sedative104166553
is    O
a    O
drug    O
which    O
is    O
a    O
benzodiazepine    O
derivative    O
;    O
it    O
is    O
a    O
water    O
soluble    O
derivative    O
of    O
diazepam    O
.    O

The    O
long    O
-    O
acting    O
active    O
metabolite    O
nordazepam    B-Sedative104166553
can    O
cause    O
extended    O
sedative    O
effects    O
at    O
high    O
doses    O
or    O
with    O
prolonged    O
use    O
,    O
and    O
may    O
produce    O
residual    O
sedation    O
upon    O
awakening    O
.    O

nordazepam    B-Sedative104166553

The    O
main    O
active    O
metabolite    O
of    O
diazepam    O
is    O
desmethyldiazepam    B-Sedative104166553
(    O
also    O
known    O
as    O
nordazepam    O
or    O
nordiazepam    O
)    O
.    O

The    O
elimination    O
half    O
-    O
life    O
of    O
diazepam    O
and    O
also    O
the    O
active    O
metabolite    O
desmethyldiazepam    B-Sedative104166553
increases    O
significantly    O
in    O
the    O
elderly    O
,    O
which    O
may    O
result    O
in    O
prolonged    O
action    O
,    O
as    O
well    O
as    O
accumulation    O
of    O
the    O
drug    O
during    O
repeated    O
administration    O
.    O

Benzodiazepines    O
with    O
a    O
half    O
-    O
life    O
of    O
more    O
than    O
24    O
hours    O
include    O
chlordiazepoxide    O
,    O
diazepam    O
,    O
clobazam    B-Sedative104166553
,    O
clonazepam    B-Sedative104166553
,    O
chlorazepinic    O
acid    O
,    O
ketazolam    B-Sedative104166553
,    O
medazepam    B-Sedative104166553
,    O
nordazepam    B-Sedative104166553
,    O
and    O
prazepam    B-Sedative104166553
.    O

difebarbamate    B-Sedative104166553
(    O
INN    O
)    O

haloxazolam    B-Sedative104166553

Diclazepam    B-Sedative104166553
,    O
or    O
2'-Chlorodiazepam    O
,    O
a    O
benzodiazepine    O
designer    O
drug    O
with    O
typical    O
sedative    O
and    O
anxiolytic    O
effects    O

fasiplon    B-Sedative104166553
(    O
INN    O
)    O

Designed    O
to    O
regulate    O
amphetamines    O
,    O
barbiturates    O
,    O
and    O
other    O
synthetics    O
,    O
the    O
34th    O
version    O
of    O
the    O
treaty    O
,    O
,    O
regulates    O
secobarbital    O
as    O
schedule    O
II    O
,    O
amobarbital    O
,    O
butalbital    O
,    O
cyclobarbital    O
,    O
and    O
pentobarbital    O
as    O
schedule    O
III    O
,    O
and    O
allobarbital    O
,    O
barbital    O
,    O
butobarbital    B-Sedative104166553
,    O
mephobarbital    O
,    O
phenobarbital    O
,    O
butabarbital    O
,    O
and    O
vinylbital    O
as    O
schedule    O
IV    O
on    O
its    O
"    O
Green    O
List    O
"    O
.    O

Asenapine    B-Sedative104166553

Asenapine    B-Sedative104166553

Asenapine    B-Sedative104166553

More    O
recently    O
the    O
site    O
was    O
closely    O
involved    O
in    O
supporting    O
the    O
introduction    O
of    O
the    O
anti    O
-    O
psychotic    O
asenapine    B-Sedative104166553
which    O
has    O
just    O
been    O
launched    O
for    O
the    O
treatment    O
of    O
schizophrenia    O
and    O
bipolar    O
disorder    O
.    O

Asenapine    B-Sedative104166553

Honokiol    B-Sedative104166553
,    O
a    O
compound    O
derived    O
from    O
"    O
Magnolia    O
officinalis    O
"    O
,    O
can    O
induce    O
paraptosis    O
in    O
human    O
leukemia    O
cells    O
.    O

Magnolol    O
,    O
honokiol    B-Sedative104166553
,    O
and    O
3,5â²-diallyl-2â²-hydroxy-4-methoxybiphenyl    O
exhibited    O
significant    O
activity    O
against    O
Gram    O
-    O
positive    O
and    O
acid    O
-    O
fast    O
bacteria    O
and    O
fungi    O
.    O

Suproclone    O
is    O
very    O
similar    O
in    O
structure    O
to    O
the    O
related    O
drug    O
suriclone    B-Sedative104166553
,    O
but    O
little    O
information    O
has    O
been    O
published    O
about    O
it    O
specifically    O
.    O

#    O
Ethylloflazepate    B-Sedative104166553

ethyl    B-Sedative104166553
loflazepate    I-Sedative104166553

For    O
example    O
,    O
mazapertine    B-Sedative104166553
,    O
aripiprazole    B-Sedative104166553
&    O
fluanisone    B-Sedative104166553
.    O

Petrichloral    B-Sedative104166553
(    O
Pentaerythritol    B-Sedative104166553
chloral    I-Sedative104166553
)    O
is    O
a    O
sedative    O
and    O
hypnotic    O
drug    O
related    O
to    O
chloral    O
hydrate    O
.    O

NMDA    B-Sedative104166553
receptor    I-Sedative104166553
modulators    I-Sedative104166553
(    O
glutamate    O
modulators    O
)    O
are    O
a    O
new    O
form    O
of    O
antipsychotic    O
that    O
are    O
in    O
Phase    O
II    O
FDA    O
study    O
.    O

:    O
N05CC03    O
Acetylglycinamide    B-Sedative104166553
chloral    I-Sedative104166553
hydrate    I-Sedative104166553

:    O
N05CC02    O
Chloralodol    B-Sedative104166553

The    O
antidote    O
for    O
an    O
overdose    O
of    O
diazepam    O
(    O
or    O
any    O
other    O
benzodiazepine    O
)    O
is    O
flumazenil    B-Sedative104166553
(    O
Anexate    O
)    O
.    O

Flumazenil    B-Sedative104166553
is    O
being    O
studied    O
as    O
a    O
potential    O
treatment    O
to    O
reduce    O
withdrawal    O
symptoms    O
.    O

Flumazenil    B-Sedative104166553
has    O
been    O
found    O
to    O
stimulate    O
the    O
reversal    O
of    O
tolerance    O
and    O
the    O
normalization    O
of    O
receptor    O
function    O
.    O

:    O
Flumazenil    B-Sedative104166553
was    O
found    O
to    O
be    O
more    O
effective    O
than    O
placebo    O
in    O
reducing    O
feelings    O
of    O
hostility    O
and    O
aggression    O
in    O
patients    O
who    O
had    O
been    O
free    O
of    O
benzodiazepines    O
for    O
4    O
-    O
266    O
weeks    O
.    O

In    O
2007    O
,    O
Hoffmann    O
â    O
La    O
Roche    O
the    O
makers    O
of    O
flumazenil    O
,    O
acknowledged    O
the    O
existence    O
of    O
protracted    O
benzodiazepine    O
withdrawal    O
syndromes    O
,    O
but    O
did    O
not    O
recommended    O
flumazenil    B-Sedative104166553
to    O
treat    O
the    O
condition    O
.    O

There    O
is    O
no    O
known    O
cure    O
for    O
protracted    O
benzodiazepine    O
withdrawal    O
syndrome    O
except    O
time    O
,    O
however    O
,    O
the    O
medication    O
flumazenil    B-Sedative104166553
was    O
found    O
to    O
be    O
more    O
effective    O
than    O
placebo    O
in    O
reducing    O
feelings    O
of    O
hostility    O
and    O
aggression    O
in    O
patients    O
who    O
had    O
been    O
free    O
of    O
benzodiazepines    O
for    O
4â266    O
weeks    O
.    O

Direct    O
binding    O
to    O
the    O
benzodiazepine    O
/    O
flumazenil    B-Sedative104166553
binding    O
site    O
of    O
the    O
GABAA    O
receptor    O
does    O
not    O
occur    O
with    O
kavain    O
enantiomers    O
.    O

Flumazenil    B-Sedative104166553
was    O
found    O
to    O
be    O
more    O
effective    O
than    O
placebo    O
in    O
reducing    O
feelings    O
of    O
hostility    O
and    O
aggression    O
in    O
patients    O
who    O
had    O
been    O
free    O
of    O
benzodiazepines    O
for    O
4â266    O
weeks    O
.    O

Detomidine    B-Sedative104166553
,    O
etc    O
.    O

Detomidine    B-Sedative104166553

loprazolam    B-Sedative104166553

Benzodiazepines    O
with    O
a    O
half    O
-    O
life    O
of    O
less    O
than    O
24    O
hours    O
include    O
alprazolam    O
,    O
bromazepam    O
,    O
brotizolam    O
,    O
flunitrazepam    B-Sedative104166553
,    O
loprazolam    B-Sedative104166553
,    O
lorazepam    O
,    O
lormetazepam    B-Sedative104166553
,    O
midazolam    O
,    O
nitrazepam    O
,    O
oxazepam    O
,    O
and    O
temazepam    O
.    O


